<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Doing business in Poland - KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</title>
	<atom:link href="https://www.kg-legal.eu/info/tag/doing-business-in-poland/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.kg-legal.eu/info/tag/doing-business-in-poland/</link>
	<description>KIELTYKA GLADKOWSKI LEGAL &#124; CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</description>
	<lastBuildDate>Tue, 17 Nov 2026 18:55:02 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	
	<item>
		<title>From Technology Transfer to Knowledge Valorisation: Managing Intellectual Assets under the EU Framework in 2026</title>
		<link>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/from-technology-transfer-to-knowledge-valorisation-managing-intellectual-assets-under-the-eu-framework-in-2026/</link>
					<comments>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/from-technology-transfer-to-knowledge-valorisation-managing-intellectual-assets-under-the-eu-framework-in-2026/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 18:55:02 +0000</pubDate>
				<category><![CDATA[IT, NEW TECHNOLOGIES, MEDIA AND COMMUNICATION TECHNOLOGY LAW]]></category>
		<category><![CDATA[academic entrepreneurship]]></category>
		<category><![CDATA[citizen engagement]]></category>
		<category><![CDATA[citizen science]]></category>
		<category><![CDATA[consortium agreements]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[ERA Act]]></category>
		<category><![CDATA[EU knowledge valorisation]]></category>
		<category><![CDATA[European Innovation Act]]></category>
		<category><![CDATA[European Research Area]]></category>
		<category><![CDATA[FP10]]></category>
		<category><![CDATA[grant agreements]]></category>
		<category><![CDATA[Horizon Europe]]></category>
		<category><![CDATA[industry-academia collaboration]]></category>
		<category><![CDATA[intellectual asset management]]></category>
		<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[IP licensing]]></category>
		<category><![CDATA[IP ownership]]></category>
		<category><![CDATA[IP valuation]]></category>
		<category><![CDATA[IP-backed finance]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[know-how protection]]></category>
		<category><![CDATA[knowledge valorisation]]></category>
		<category><![CDATA[open innovation]]></category>
		<category><![CDATA[open science]]></category>
		<category><![CDATA[Poland]]></category>
		<category><![CDATA[Polish higher education law]]></category>
		<category><![CDATA[R&D agreements]]></category>
		<category><![CDATA[research and innovation]]></category>
		<category><![CDATA[Research Commercialisation]]></category>
		<category><![CDATA[research funding]]></category>
		<category><![CDATA[research partnerships]]></category>
		<category><![CDATA[social innovation]]></category>
		<category><![CDATA[standardisation]]></category>
		<category><![CDATA[Technology Transfer]]></category>
		<category><![CDATA[technology transfer offices]]></category>
		<category><![CDATA[university IP policies]]></category>
		<category><![CDATA[university spin-offs]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=9040</guid>

					<description><![CDATA[<p>Publication date: November 17, 2026 For almost two decades, European universities measured research impact in patents, licences and spin-offs. The EU has since moved the goalposts. Under Council Recommendation (EU) 2022/2415 and four codes of practice adopted in 2023-2024, the benchmark is now “knowledge valorisation”: turning all intellectual assets, from data and know-how to standards [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/from-technology-transfer-to-knowledge-valorisation-managing-intellectual-assets-under-the-eu-framework-in-2026/">From Technology Transfer to Knowledge Valorisation: Managing Intellectual Assets under the EU Framework in 2026</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: November 17, 2026</mark></strong></p>



<p><strong>For almost two decades, European universities measured research impact in patents, licences and spin-offs. The EU has since moved the goalposts. Under Council Recommendation (EU) 2022/2415 and four codes of practice adopted in 2023-2024, the benchmark is now “knowledge valorisation”: turning all intellectual assets, from data and know-how to standards and citizen science, into economic and societal value. In 2025-2026 the policy began to harden into binding law, with the European Innovation Act proposed in September 2026, a European Research Area (ERA) Act in the pipeline and the next Framework Programme (FP10, 2028-2034) under negotiation. Polish universities, still operating largely on a 2008-era technology transfer model under the Law on Higher Education and Science, have a narrowing window to adapt.</strong></p>



<span id="more-9040"></span>



<h2 class="wp-block-heading"><a>Soft law with hard consequences</a></h2>



<p>EU recommendations are not binding, yet they shape how research institutions write their internal rules and how projects get funded. Under Article 288 TFEU, recommendations and opinions “have no binding force”. Under Article 292 TFEU, the Council adopts recommendations, and the Commission (and, in specific cases, the European Central Bank) may also do so.</p>



<p>A recommendation creates no sanctions and no enforceable claims. Implementation depends on the goodwill of Member States and institutions. In practice, however, recommendations set the European standard: they are reflected in grant agreements, national strategies, evaluation criteria and university regulations. Ignoring them rarely carries a legal penalty, but it increasingly carries a funding and reputational one.</p>



<h2 class="wp-block-heading"><a>The 2008 model: technology transfer and the rise of TTOs</a></h2>



<p>On 10 April 2008 the Commission adopted Recommendation 2008/416/EC on the management of intellectual property in knowledge transfer activities, with a Code of Practice for universities and other public research organisations (Annex I). Divergent national rules were hampering the European Research Area and cross-border cooperation. The goal was to link science more closely with industry and turn publicly funded research into tangible economic benefit.</p>



<p>The Code rested on three sets of principles:</p>



<ul class="wp-block-list">
<li><strong>Internal IP policy:</strong> adopt and publicise an IP policy, set clear rules on disclosure of commercially promising ideas and on ownership of results, protect IP and give staff incentives to engage.</li>



<li><strong>Knowledge transfer policy:</strong> consider all exploitation routes (licensing, spin-offs) and partners; additional revenue should not be the primary goal; secure access to professional transfer, legal, financial and IP enforcement services.</li>



<li><strong>Collaborative and contract research:</strong> align the rules with each party’s mission, settle IP ownership and access rights as early as possible, ideally before the research starts.</li>
</ul>



<p>Points 6 and 7 of Annex II called for resources, incentives and trained staff such as technology transfer officers. This drove the creation of technology transfer offices (TTOs) across Europe, focused on patent filings, patent sales, licensing and industry relations.</p>



<h2 class="wp-block-heading"><a>The 2022 shift: from transfer to valorisation</a></h2>



<p>Council Recommendation (EU) 2022/2415 of 2 December 2022 on the guiding principles for knowledge valorisation formally replaced the 2008 Recommendation. Its preamble acknowledges the gains of the transfer model but calls for a move beyond technology and beyond a narrow, licence-and-patent view of value.</p>



<p>Knowledge valorisation is defined as the process of creating social and economic value from knowledge by linking different areas and sectors, and by transforming data, know-how and research results into sustainable products, services, solutions and knowledge-based policies that benefit society. Valorisation thus becomes a driver of social development, involving citizens and informing public policy.</p>



<p>The Recommendation sets seven guiding principles:</p>



<ol class="wp-block-list">
<li><strong>Valorisation in R&amp;I policy:</strong> support structures, resources, strategies and practices; the widest societal uptake; equality, diversity and inclusion.</li>



<li><strong>Skills and capacities:</strong> competences for all stakeholders, mobility between academia, industry and the public sector, interdisciplinary work including social sciences, humanities and the arts.</li>



<li><strong>Incentives:</strong> for all R&amp;I actors to practise valorisation, and for businesses, society and public authorities to co-create and use new solutions.</li>



<li><strong>Intellectual asset management:</strong> organisational policies and practices, awareness of the international context and sovereignty, maximising socio-economic benefits for the EU, open science and open innovation.</li>



<li><strong>Public funding programmes:</strong> valorisation principles built into publicly funded research, with early-stage funding and support for intermediaries.</li>



<li><strong>Mutual learning:</strong> sharing good practice, common specifications and benchmarking.</li>



<li><strong>Indicators, monitoring and evaluation:</strong> common definitions and metrics across valorisation channels, aligned with ERA monitoring.</li>
</ol>



<h2 class="wp-block-heading"><a>2008 vs 2022 at a glance</a></h2>



<figure class="wp-block-table"><table class="has-luminous-vivid-amber-background-color has-background has-fixed-layout"><thead><tr><td>&nbsp;</td><td>Recommendation 2008/416/EC</td><td>Recommendation (EU) 2022/2415</td></tr></thead><tbody><tr><td>Concept</td><td>Knowledge transfer (research, consultancy, licensing); commercialisation for economic growth</td><td>Knowledge valorisation: economic, social, policy and environmental value</td></tr><tr><td>Addressees</td><td>Public research organisations and universities</td><td>The whole R&amp;I ecosystem: universities, NGOs, private investors, individuals, businesses, intermediaries, public authorities</td></tr><tr><td>Role of citizens</td><td>Passive recipients of economic benefits</td><td>Active participants in valorisation</td></tr><tr><td>Implementation</td><td>A single Code of Practice (Annex I)</td><td>Targeted codes of practice, with new codes added as needed</td></tr></tbody></table></figure>



<p>Replacing the 2008 Recommendation did not end its practice overnight. Many grant agreements, funding schemes and university regulations still in force refer to its principles, so research institutions must be able to operate under both frameworks at once.</p>



<h2 class="wp-block-heading"><a>Four codes of practice that put the principles to work</a></h2>



<p>Between March 2023 and March 2024 the Commission adopted four codes of practice implementing Recommendation 2022/2415. Each translates the guiding principles into operational guidance for a specific channel of valorisation.</p>



<figure class="wp-block-table"><table class="has-luminous-vivid-amber-background-color has-background has-fixed-layout"><thead><tr><td>Code of practice</td><td>Adopted</td><td>Core recommendations</td></tr></thead><tbody><tr><td>Management of intellectual assets for knowledge valorisation in the ERA (Recommendation (EU) 2023/499)</td><td>1 March 2023</td><td>Adopt an intellectual asset management strategy compatible with open science and open innovation; clarify ownership and terms early in joint R&amp;I; manage the path from creation to market through control measures, IP valuation, monitoring, transfer and licensing</td></tr><tr><td>Standardisation in the ERA (Recommendation (EU) 2023/498)</td><td>1 March 2023</td><td>Adopt a standardisation policy (standalone or within the IP policy); recognise standardisation in researcher careers and assessment; adapt TTOs; build standards into project design and impact; national support for SMEs and start-ups</td></tr><tr><td>Citizen engagement for knowledge valorisation (Recommendation (EU) 2024/736)</td><td>1 March 2024</td><td>Build an enabling environment with an organisational strategy, inclusion and gender equality, proper intellectual asset management, recognition of participants’ time and an evaluation framework; manage engagement with clear incentives, methods, communication and digital tools</td></tr><tr><td>Industry-academia co-creation for knowledge valorisation (Recommendation (EU) 2024/774)</td><td>1 March 2024</td><td>Strategy, awareness, skills, lifelong learning and networks; conditions for successful partnerships; support for intermediaries; evaluation of co-created value and impact</td></tr></tbody></table></figure>



<p>The code on intellectual assets is the true successor to the 2008 Code. Its key move is conceptual: “intellectual assets” are broader than formal IP rights such as patents and copyright. They also cover publications, data, know-how and other R&amp;I results, widening the scope for value creation and social innovation. The standardisation code treats standards as a valorisation route in their own right, supporting the free movement of goods, services and data, interoperability, the EU’s climate goals and its strategic autonomy.</p>



<h2 class="wp-block-heading"><a>2025-2026: from soft law towards binding rules</a></h2>



<p>The valorisation agenda is moving from voluntary guidance into legislation. Four developments matter for anyone managing intellectual assets in a research setting.</p>



<figure class="wp-block-table"><table class="has-luminous-vivid-amber-background-color has-background has-fixed-layout"><thead><tr><td>Instrument</td><td>Status (as of November 2026)</td><td>Why it matters for intellectual assets</td></tr></thead><tbody><tr><td>European Innovation Act</td><td>Proposed by the Commission on 9 September 2026, with a separate proposal for a Council Recommendation on regulatory sandboxes; now in the ordinary legislative procedure</td><td>Common EU methodology for IP valuation, a voluntary EUIPO certification scheme for IP valuators, a voluntary IP marketplace, an EUIPO competence centre on IP-backed finance; common procedure for joint cross-border R&amp;D procurement, with the contractor keeping IP ownership by default in pre-commercial procurement</td></tr><tr><td>ERA Act</td><td>Announced for autumn 2026; the Commission indicated its core would be a regulation, possibly with parts as a directive</td><td>First binding legal framework for the European Research Area (“fifth freedom” of knowledge circulation), with focus on the 3% R&amp;D target, research security, open science and research infrastructures</td></tr><tr><td>FP10 / Horizon Europe 2028-2034 (COM(2025) 543)</td><td>Proposed 16 July 2025; under negotiation for a planned start on 1 January 2028</td><td>The draft rules for participation define “valorisation” as the use of results in further activities beyond the action, including commercial deployment; stronger emphasis on impact and exploitation</td></tr><tr><td>ERA Policy Agenda 2025-2027 (Council Recommendation of 24 June 2025)</td><td>In force (soft law)</td><td>Continues “upscaling knowledge valorisation capacities and activities” as a structural ERA policy</td></tr></tbody></table></figure>



<p>The Innovation Act changes the economics of intellectual assets most directly. The Commission estimates a financing gap of up to EUR 18 billion a year for asset-light firms and expects its IP measures to unlock an additional EUR 10.2 billion a year in IP-backed venture and debt finance. For universities, a recognised valuation methodology could make their portfolios bankable for spin-offs. Commentators note an open question: the EUIPO’s expertise is in trademarks and designs, while patents fall to the European Patent Office, which is not an EU body.</p>



<p>The proposals are not yet law and their final texts may differ materially. The direction is clear, however: valorisation, IP valuation and impact reporting are becoming conditions of funding and market access, not optional good practice.</p>



<h2 class="wp-block-heading"><a>The Polish perspective: a 2008 model in a 2022 world</a></h2>



<p>Poland’s Law of 20 July 2018 on Higher Education and Science (PSWiN, consolidated text Dz.U. 2024 item 1571, as amended) reflects both approaches, but its operative mechanisms remain anchored in the 2008 transfer model.</p>



<ul class="wp-block-list">
<li><strong>Statutory tasks (Art. 11(1)):</strong> alongside classic knowledge and technology transfer to the economy (point 3), universities must disseminate scientific and cultural achievements (point 9) and act for local and regional communities (point 10). The modern, socially engaged mission is present, at least on paper.</li>



<li><strong>IP regulations (Art. 152(1)):</strong> the university senate must adopt rules on managing copyright, related rights and industrial property and on commercialisation, including creator remuneration, procedures and revenue sharing. This mirrors the intellectual asset management code (Recommendation 2023/499).</li>



<li><strong>Commercialisation procedure (Art. 154):</strong> an employee must inform the university of research results and related know-how. The employee has 14 days to declare interest in commercialisation by the university, which has 3 months to decide. If the university misses the deadline, it must offer the employee, within 30 days, an unconditional transfer of rights for consideration. Absent such a contract, the rights stay with the university. These rules do not apply where funding terms provide otherwise (Art. 154(5)).</li>



<li><strong>Revenue sharing (Art. 155):</strong> in university-led commercialisation the creator receives at least 50% of proceeds (direct) or 50% of the special-purpose company’s proceeds (indirect), reducible by no more than 25% of direct costs. Where the researcher commercialises independently, the university receives 25%, on the same cost basis. University regulations (e.g. at the Jagiellonian University and the University of Warsaw) often raise the creator’s share as an incentive.</li>



<li><strong>Technology transfer centres (Art. 148)</strong> handle direct commercialisation: sale, licensing, lease. <strong>Special-purpose companies (Art. 149)</strong>, single-shareholder companies set up by the rector with senate consent, handle indirect commercialisation and ring-fence risk.</li>
</ul>



<p>In practice, both technology transfer centres and special-purpose companies focus on classic commercialisation and business partnerships, in the spirit of 2008. Citizen engagement and social innovation, central to the 2022 framework, have little statutory footing. The Ministry of Science and Higher Education is preparing a broader PSWiN amendment, including a new model of research evaluation, which offers a natural opportunity to close this gap.</p>



<h2 class="wp-block-heading"><a>Case study: bringing a mid-sized university up to date</a></h2>



<p>Consider a mid-sized public university with no intellectual asset or valorisation policy. It still follows the 2008 model: commercialisation, patenting and industry cooperation through its TTO. To align with current EU policy, its IP regulations should cover at least the following:</p>



<ul class="wp-block-list">
<li><strong>Ownership of results:</strong> economic rights to results created within employment duties vest in the university and revert to the creator if the university declines to commercialise; moral rights, being inalienable, always remain with the creator.</li>



<li><strong>Mandatory pre-publication disclosure:</strong> if rights vest in the university, results must be reported before publication, since early disclosure can destroy patentability.</li>



<li><strong>Assessment of implementation potential:</strong> whether results are novel and carry real economic or social value, in line with valorisation goals.</li>



<li><strong>Funding of legal protection:</strong> who bears the costs of patent filings and prosecution.</li>



<li><strong>Confidentiality and conflicts of interest:</strong> mandatory NDAs for research information and results, and a negotiation and amicable dispute resolution procedure between the university and the creator.</li>
</ul>



<p>A simple disclosure process could run in four stages:</p>



<ol class="wp-block-list">
<li><strong>Disclosure:</strong> the researcher submits a standard form to the TTO.</li>



<li><strong>Assessment (within 14 days):</strong> TTO specialists assess novelty and implementation potential.</li>



<li><strong>Decision (within 3 months):</strong> the competent science committee decides on legal protection or returns the rights to the creator.</li>



<li><strong>Valorisation route:</strong> depending on context, a spin-off, a partnership with industry, or open science publication.</li>
</ol>



<p>Revenue from licences or spin-off equity could be split <strong>50% to the creator</strong> (a strong incentive to disclose), <strong>25% to the faculty or institute</strong> (to sustain the team and further research) and <strong>25% to the university</strong> (to fund valorisation activity). This is consistent with the PSWiN floor of 50% for the creator.</p>



<p>Finally, valorisation is not only commercial. Social innovation and citizen engagement can include community programmes (training, volunteering), citizen participation in research (for example health or environmental surveys), cooperation with local government and NGOs, and open access publication where social value is high and commercialisation is not needed.</p>



<h2 class="wp-block-heading"><a>Practical recommendations for research institutions</a></h2>



<ol class="wp-block-list">
<li><strong>Turn technology transfer centres into valorisation centres.</strong> Look beyond purely commercial goals to social, policy and environmental value; engage in local initiatives; promote open science, social innovation and cooperation with non-business partners.</li>



<li><strong>Build an incentive system for the whole R&amp;I ecosystem.</strong> Give valorisation achievements (science communication, citizen collaboration, contributions to standards) the same weight as publications and teaching in career and evaluation.</li>



<li><strong>Set up permanent citizen engagement mechanisms.</strong> Community programmes on locally relevant issues and public consultation on high-impact projects, with transparent results. For citizens, real influence on their surroundings (for example air quality studies) and certified participation that adds value on the job market.</li>



<li><strong>Prepare intellectual asset portfolios for the Innovation Act.</strong> Map and document intellectual assets beyond patents (data, know-how, software, standards contributions), introduce consistent valuation practices and track the EU valuation framework so that spin-offs can use IP as collateral.</li>



<li><strong>Future-proof funding contracts.</strong> Align IP clauses in consortium, grant and R&amp;D procurement agreements with the FP10 rules and the Innovation Act’s default allocation of IP in pre-commercial procurement.</li>
</ol>



<h2 class="wp-block-heading"><a>Conclusion</a></h2>



<p>The EU has moved from a 2008 model built on patents and licences to a 2022 framework that treats every intellectual asset as a potential source of economic and social value, and is now giving that framework legal teeth. Polish law and practice have absorbed the first model well but only partly the second. Institutions that update their IP regulations, incentives and asset management now will be better placed for FP10 funding, for IP-backed finance under the Innovation Act and for the ERA Act’s binding commitments.</p>



<h2 class="wp-block-heading"><a>Sources</a></h2>



<ul class="wp-block-list">
<li><a href="https://eur-lex.europa.eu/eli/reco/2022/2415/oj" target="_blank" rel="noreferrer noopener">Council Recommendation (EU) 2022/2415 on the guiding principles for knowledge valorisation</a></li>



<li><a href="https://eur-lex.europa.eu/eli/reco/2023/499/oj" target="_blank" rel="noreferrer noopener">Commission Recommendation (EU) 2023/499 on the code of practice on intellectual asset management</a></li>



<li><a href="https://eur-lex.europa.eu/eli/C/2025/3593/oj" target="_blank" rel="noreferrer noopener">Council Recommendation of 24 June 2025 on the ERA Policy Agenda 2025-2027</a></li>



<li><a href="https://www.faegredrinker.com/en/insights/publications/2026/9/the-european-innovation-act-how-the-law-could-change-ip-investment-in-the-eu" target="_blank" rel="noreferrer noopener">Faegre Drinker: The European Innovation Act and IP investment (28 September 2026)</a></li>



<li><a href="https://www.era.gv.at/news-items/commission-proposes-new-european-innovation-act-to-speed-up-the-path-from-research-to-market/" target="_blank" rel="noreferrer noopener">ERA Portal Austria: Commission proposes European Innovation Act (9 September 2026)</a></li>



<li><a href="https://www.era.gv.at/news-items/era-forum-focuses-on-era-act-talent-attraction-and-era-policy-agenda-implementation/" target="_blank" rel="noreferrer noopener">ERA Portal Austria: ERA Forum on the ERA Act (11 June 2026)</a></li>



<li><a href="https://www.eumonitor.nl/9353000/1/j4nvhdfcs8bljza_j9vvik7m1c3gyxp/vmp4v5la67u0" target="_blank" rel="noreferrer noopener">FP10 proposal, COM(2025) 543</a></li>
</ul>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<p><em>KG Legal Kiełtyka Gładkowski·office@kg-legal.pl · www.kg-legal.eu</em></p>
<p> </p>



<p>Services</p>



<p><strong>KIELTYKA GLADKOWSKI</strong> is a Polish business law firm headquartered in Warsaw and Krakow, with a New York office under the iSTART1 brand. Building on a practice dating back to 1981, we advise clients in the following areas.</p>



<h1 class="wp-block-heading">Explore our services</h1>



<p>Select a practice area to learn more.</p>



<figure class="wp-block-table"><table class="has-luminous-vivid-amber-background-color has-background has-fixed-layout"><thead><tr><td><strong>Business<br>&amp; Finance</strong></td><td><strong>Technology<br>&amp; IP</strong></td><td><strong>Energy<br>&amp; Projects</strong></td><td><strong>Sectors &amp;<br>Cross Border</strong></td><td><strong>Private Clients<br>&amp; Disputes</strong></td></tr></thead><tbody><tr><td><a href="https://www.kg-legal.pl/investment-law-and-processes-in-poland-1/">Commercial &amp; Corporate</a> <a href="https://www.kg-legal.eu/polish-limited-liability-company-legal-support-in-operational-business-maintenance-and-representation-of-shareholders-in-court/">Polish LLCs</a> <a href="https://www.kg-legal.eu/employment-law-and-collective-labour-law-in-poland-including-employment-contracts/">Employment Law</a></td><td><a href="https://www.kg-legal.pl/it-bio-it-new-technologies-media-law-1/">IT, IP, Media &amp; New Tech</a> <a href="https://www.kg-legal.eu/trademarks-and-brand-protection/">Trademarks &amp; Brand Protection</a></td><td><a href="https://www.kg-legal.eu/green-transition/">Green Transition</a> <a href="https://www.kg-legal.eu/energy-transformation-in-poland-main-assumptions-of-the-polish-energy-policy-2040-2/">Energy Policy 2040</a></td><td><a href="https://www.kg-legal.pl/pharmaceutical-life-sciences-healthcare-law-1/">Pharma, Life Sciences &amp; Healthcare</a> <a href="https://www.kg-legal.eu/pharmaceutical-law/">Pharmaceutical Law</a></td><td><a href="https://www.kg-legal.eu/private-client-desk/">Private Client Desk</a> <a href="https://www.kg-legal.eu/hnw-and-next-gen-wealth/">HNW &amp; Next Gen Wealth</a></td></tr><tr><td><a href="https://www.kg-legal.eu/venture-capital-and-private-equity/">Venture Capital &amp; Private Equity</a> <a href="https://www.kg-legal.eu/stock-exchange-and-securities-law-in-poland/">Stock Exchange &amp; Securities</a> <a href="https://www.kg-legal.eu/markets-in-modern-and-conventional-financial-instruments-including-tokens-crypto-assets-packaged-retail-and-insurance-based-investment-products/">Financial Instruments &amp; Crypto</a></td><td><a href="https://www.kg-legal.eu/artificial-intelligence-ai-law-poland-eu/">AI Sector</a> <a href="https://www.kg-legal.eu/data-centers/">Data Centers</a></td><td><a href="https://www.kg-legal.eu/regulatory-law-of-the-energy-sector-in-poland/">Energy Sector</a> <a href="https://www.kg-legal.eu/green-energy-law-renewable-energy-law/">Renewable Energy</a></td><td><a href="https://www.kg-legal.eu/medical-devices-including-medical-devices-law-under-combined-atmps/">Medical Devices</a> <a href="https://www.kg-legal.eu/food-law/">Food Law</a></td><td><a href="https://www.kg-legal.eu/international-divorces/">International Divorces</a> <a href="https://www.kg-legal.eu/international-family-law/">International Family Law</a></td></tr><tr><td><a href="https://www.kg-legal.eu/agreements-and-contracts/">Agreements &amp; Contracts</a> <a href="https://www.kg-legal.eu/contracts-in-the-international-trade-smart-contracts/">International Trade &amp; Smart Contracts</a></td><td><a href="https://www.kg-legal.eu/data-privacy-and-data-protection/">Data Privacy &amp; Protection</a> <a href="https://www.kg-legal.pl/cybersecurity/">Cybersecurity</a></td><td><a href="https://www.kg-legal.eu/biofuels-and-biocomponents/">Biofuels &amp; Biocomponents</a> <a href="https://www.kg-legal.eu/offshore-wind-farms/">Offshore Wind</a></td><td><a href="https://www.kg-legal.eu/art-market/">Art Market</a> <a href="https://www.kg-legal.eu/legal-services-in-fashion-law/">Fashion</a></td><td><a href="https://www.kg-legal.eu/cross-border-inheritance-matters/">Cross Border Inheritance</a> <a href="https://www.kg-legal.eu/immigration-law-business-immigration-polish-passport/">Immigration &amp; Polish Passports</a></td></tr><tr><td><a href="https://www.kg-legal.eu/offshore-companies-tax-optimization/">Offshore Companies &amp; Tax</a></td><td><a href="https://www.kg-legal.eu/distributed-ledger-technology-law/">Distributed Ledger Technology</a> <a href="https://www.kg-legal.eu/metaverse-and-web3-legal-environment/">Metaverse &amp; Web3</a></td><td><a href="https://www.kg-legal.eu/greenfield-in-poland/">Greenfield Investment</a> <a href="https://www.kg-legal.eu/kieltyka-gladkowski-provides-assistance-in-the-area-of-european-partnerships-in-horizon-europe-programme/">Horizon Europe</a></td><td><a href="https://www.kg-legal.pl/cross-border-cases-1/">Cross Border Practice</a> <a href="https://www.kg-legal.eu/customs-and-tariffs-support-for-international-traders-in-poland-and-eu/">Customs &amp; Tariffs</a></td><td><a href="https://www.kg-legal.eu/asset-tracing-in-poland-for-international-creditors/">Asset Tracing in Poland</a> <a href="https://www.kg-legal.eu/asset-tracing/">Asset Tracing</a> <a href="https://www.kg-legal.eu/business-investigations-private-detective-services/">Business Investigations</a></td></tr><tr><td><a href="https://www.kg-legal.eu/dissolution-and-liquidation-of-capital-companies/">Company Dissolution &amp; Liquidation</a> <a href="https://www.kg-legal.eu/cross-border-bankruptcy-in-poland/">Cross Border Bankruptcy</a></td><td><a href="https://www.kg-legal.eu/dual-use-technology-law/">Dual Use Technology</a> <a href="https://www.kg-legal.eu/drone-uas-law/">Drones &amp; UAS</a> <a href="https://www.kg-legal.eu/defence-and-space-sector/">Defence &amp; Space</a></td><td><a href="https://www.kg-legal.eu/industrial-micro-and-public-macro-infrastructure/">Infrastructure</a> <a href="https://www.kg-legal.eu/construction/">Construction</a> <a href="https://www.kg-legal.eu/public-private-partnerships/">Public Private Partnerships</a></td><td><a href="https://www.kg-legal.eu/sworn-certified-legal-translations-of-documents-and-contracts/">Sworn &amp; Certified Legal Translations</a></td><td><a href="https://www.kg-legal.eu/litigation-and-representation-of-international-clients-before-the-polish-courts/">Litigation in Polish Courts</a> <a href="https://www.kg-legal.eu/litigation-antitrust-and-competition-law/">Litigation &amp; Competition</a></td></tr></tbody></table></figure>



<p>Service directory: <a href="https://www.kg-legal.eu/services/">kg-legal.eu/services</a></p>
<p> </p>



<p>KG LEGAL KIELTYKA GLADKOWSKI offers legal support for research commercialisation and knowledge valorisation in Poland. Our assistance covers intellectual asset policies, technology licensing, R&amp;D and consortium agreements, university spin-offs and IP obligations under funding agreements.</p>



<p>We help research organisations and commercial partners clarify ownership, access rights and responsibilities when developing and using research results.</p>



<p>Contact: <a href="mailto:office@kg-legal.pl">office@kg-legal.pl</a>.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/from-technology-transfer-to-knowledge-valorisation-managing-intellectual-assets-under-the-eu-framework-in-2026/">From Technology Transfer to Knowledge Valorisation: Managing Intellectual Assets under the EU Framework in 2026</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/from-technology-transfer-to-knowledge-valorisation-managing-intellectual-assets-under-the-eu-framework-in-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Thuringia Meets Małopolska: KG Legal KIELTYKA GLADKOWSKI at the Business Meeting with Minister-President Mario Voigt at SOLARIS</title>
		<link>https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/thuringia-meets-malopolska-kg-legal-kieltyka-gladkowski-at-the-business-meeting-with-minister-president-mario-voigt-at-solaris/</link>
					<comments>https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/thuringia-meets-malopolska-kg-legal-kieltyka-gladkowski-at-the-business-meeting-with-minister-president-mario-voigt-at-solaris/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 13:43:41 +0000</pubDate>
				<category><![CDATA[INVESTMENT LAW AND PROCESSES IN POLAND]]></category>
		<category><![CDATA[advanced manufacturing]]></category>
		<category><![CDATA[AHK Polska]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[biotechnology]]></category>
		<category><![CDATA[Business in Małopolska]]></category>
		<category><![CDATA[Cross-Border Legal Services]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[Gaia AI Factory]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[German business in Poland]]></category>
		<category><![CDATA[German investment in Poland]]></category>
		<category><![CDATA[industrial automation]]></category>
		<category><![CDATA[Intellectual Property]]></category>
		<category><![CDATA[KG Legal Kieltyka Gladkowski]]></category>
		<category><![CDATA[Kraków]]></category>
		<category><![CDATA[LEG Thüringen]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<category><![CDATA[Mario Voigt]]></category>
		<category><![CDATA[market entry in Poland]]></category>
		<category><![CDATA[Małopolska]]></category>
		<category><![CDATA[mechatronics]]></category>
		<category><![CDATA[Medical devices]]></category>
		<category><![CDATA[MedTech]]></category>
		<category><![CDATA[microelectronics]]></category>
		<category><![CDATA[Polish-German business cooperation]]></category>
		<category><![CDATA[R&D cooperation]]></category>
		<category><![CDATA[research agreements]]></category>
		<category><![CDATA[Research and Development]]></category>
		<category><![CDATA[Research Commercialisation]]></category>
		<category><![CDATA[SOLARIS]]></category>
		<category><![CDATA[technology partnerships]]></category>
		<category><![CDATA[Technology Transfer]]></category>
		<category><![CDATA[Thuringia]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=9035</guid>

					<description><![CDATA[<p>Publication date: November 17, 2026 Kraków, 17 November 2026 Today KG Legal is taking part in a business meeting with a delegation from the Free State of Thuringia, led by Minister-President Mario Voigt, hosted at the National Synchrotron Radiation Centre SOLARIS in Kraków. The meeting is organised by the Polish-German Chamber of Industry and Commerce [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/thuringia-meets-malopolska-kg-legal-kieltyka-gladkowski-at-the-business-meeting-with-minister-president-mario-voigt-at-solaris/">Thuringia Meets Małopolska: KG Legal KIELTYKA GLADKOWSKI at the Business Meeting with Minister-President Mario Voigt at SOLARIS</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: November 17, 2026</mark></strong></p>



<p><em>Kraków, 17 November 2026</em></p>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="538" src="https://www.kg-legal.eu/wp-content/uploads/2026/11/Blog-header-1200×630@1x-1024x538.png" alt="" class="wp-image-9036" srcset="https://www.kg-legal.eu/wp-content/uploads/2026/11/Blog-header-1200×630@1x-1024x538.png 1024w, https://www.kg-legal.eu/wp-content/uploads/2026/11/Blog-header-1200×630@1x-300x158.png 300w, https://www.kg-legal.eu/wp-content/uploads/2026/11/Blog-header-1200×630@1x-768x403.png 768w, https://www.kg-legal.eu/wp-content/uploads/2026/11/Blog-header-1200×630@1x.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



<p>Today KG Legal is taking part in a business meeting with a delegation from the Free State of Thuringia, led by Minister-President Mario Voigt, hosted at the National Synchrotron Radiation Centre SOLARIS in Kraków. The meeting is organised by the Polish-German Chamber of Industry and Commerce (AHK Polska) together with the Marshal&#8217;s Office of the Małopolska Region and the Business in Małopolska centre, with LEG Thüringen, the Thuringian economic development agency, as a partner.</p>



<span id="more-9035"></span>



<p>The aim is simple and ambitious at the same time: to build direct business relationships between companies, research institutes and institutions from Thuringia and Małopolska, and to open new avenues for cooperation in industry, technology and R&amp;D.</p>



<h2 class="wp-block-heading">A venue that sets the tone</h2>



<p>It is hard to imagine a better setting for a meeting about science-driven business than SOLARIS, Poland&#8217;s synchrotron facility in Kraków. The programme combines an official opening with representatives of both regions and SOLARIS, presentations on the economic and technological potential of Małopolska and Thuringia, a presentation of the Polish AI factory Gaia AI Factory, and a guided tour of the synchrotron. The afternoon closes with short company profiles from the German participants and a networking session dedicated to one-to-one conversations.</p>



<h2 class="wp-block-heading">Who came from Thuringia</h2>



<p>The Thuringian delegation reflects the region&#8217;s strengths in high technology and advanced manufacturing. It includes medtech companies such as 3di GmbH (patient-specific implants and 3D surgical models) and HEMA Orthopädische Systeme GmbH (orthopaedic solutions and medical technology), leading research organisations such as Fraunhofer IOF in Jena (photonics and optical systems), the DLR Institute for Data Science in Jena (AI and data analysis), IMMS GmbH (microelectronics, mechatronics, sensor systems and AI) and iba e.V. (bioprocess and analytical technologies), as well as industrial companies GSM GmbH and GSN Maschinen-Anlagen-Service GmbH, the certification body TÜV Thüringen e.V. and LEG Thüringen.</p>



<p>The focus sectors &#8211; microelectronics, mechatronics, industrial automation, biotechnology, life sciences and medtech &#8211; overlap closely with Małopolska&#8217;s own innovation profile, including its life sciences cluster, universities and research infrastructure.</p>



<h2 class="wp-block-heading">Where law meets technology</h2>



<p>For KG Legal, these are familiar sectors. Life sciences, healthcare, medtech, AI and data protection are at the core of our practice, and we regularly advise foreign companies, including German businesses, entering or expanding in Poland. Cross-border technology cooperation tends to raise a recurring set of legal questions, and it pays to address them early:</p>



<ul class="wp-block-list">
<li><strong>Medical devices and life sciences products</strong> &#8211; placing products on the Polish market, Polish-language labelling and instructions for use, obligations towards the Polish regulator (URPL), distribution models and public procurement for hospitals.</li>



<li><strong>R&amp;D partnerships with universities and research institutes</strong> &#8211; ownership and licensing of intellectual property, publication rights, commercialisation of research results and spin-out structures, as well as EU and national grant funding.</li>



<li><strong>AI and data</strong> &#8211; compliance with the EU AI Act, GDPR and the specific rules on health data, including in joint research projects.</li>



<li><strong>Market entry and operations</strong> &#8211; company set-up, contracts with Polish partners and distributors, employment, and effective dispute resolution across borders.</li>
</ul>



<p>Poland and Germany share a single market and a long history of economic ties, but successful cooperation still depends on getting the details right on both sides of the border.</p>



<h2 class="wp-block-heading">Looking ahead</h2>



<p>We thank AHK Polska, the Marshal&#8217;s Office of the Małopolska Region, Business in Małopolska, LEG Thüringen and NCPS SOLARIS for bringing the two regions together. Meetings like this one show how much potential lies in Polish-German cooperation in science and technology, and we look forward to following up on today&#8217;s conversations.</p>



<p>If your organisation is considering projects in Poland, or cooperation with partners in Małopolska, our team in Kraków and Warsaw will be glad to help. You can reach us at office@kg-legal.pl.</p>
<p> </p>



<h2 class="wp-block-heading">Services</h2>



<p><strong>KIELTYKA GLADKOWSKI</strong> is a Polish business law firm headquartered in Warsaw and Krakow, with a New York office under the iSTART1 brand. Building on a practice dating back to 1981, we advise clients in the following areas.</p>



<h1 class="wp-block-heading">Explore our services</h1>



<p>Select a practice area to learn more.</p>



<figure class="wp-block-table"><table class="has-luminous-vivid-amber-background-color has-background has-fixed-layout"><thead><tr><td><strong>Business<br>&amp; Finance</strong></td><td><strong>Technology<br>&amp; IP</strong></td><td><strong>Energy<br>&amp; Projects</strong></td><td><strong>Sectors &amp;<br>Cross Border</strong></td><td><strong>Private Clients<br>&amp; Disputes</strong></td></tr></thead><tbody><tr><td><a href="https://www.kg-legal.pl/investment-law-and-processes-in-poland-1/">Commercial &amp; Corporate</a> <a href="https://www.kg-legal.eu/polish-limited-liability-company-legal-support-in-operational-business-maintenance-and-representation-of-shareholders-in-court/">Polish LLCs</a> <a href="https://www.kg-legal.eu/employment-law-and-collective-labour-law-in-poland-including-employment-contracts/">Employment Law</a></td><td><a href="https://www.kg-legal.pl/it-bio-it-new-technologies-media-law-1/">IT, IP, Media &amp; New Tech</a> <a href="https://www.kg-legal.eu/trademarks-and-brand-protection/">Trademarks &amp; Brand Protection</a></td><td><a href="https://www.kg-legal.eu/green-transition/">Green Transition</a> <a href="https://www.kg-legal.eu/energy-transformation-in-poland-main-assumptions-of-the-polish-energy-policy-2040-2/">Energy Policy 2040</a></td><td><a href="https://www.kg-legal.pl/pharmaceutical-life-sciences-healthcare-law-1/">Pharma, Life Sciences &amp; Healthcare</a> <a href="https://www.kg-legal.eu/pharmaceutical-law/">Pharmaceutical Law</a></td><td><a href="https://www.kg-legal.eu/private-client-desk/">Private Client Desk</a> <a href="https://www.kg-legal.eu/hnw-and-next-gen-wealth/">HNW &amp; Next Gen Wealth</a></td></tr><tr><td><a href="https://www.kg-legal.eu/venture-capital-and-private-equity/">Venture Capital &amp; Private Equity</a> <a href="https://www.kg-legal.eu/stock-exchange-and-securities-law-in-poland/">Stock Exchange &amp; Securities</a> <a href="https://www.kg-legal.eu/markets-in-modern-and-conventional-financial-instruments-including-tokens-crypto-assets-packaged-retail-and-insurance-based-investment-products/">Financial Instruments &amp; Crypto</a></td><td><a href="https://www.kg-legal.eu/artificial-intelligence-ai-law-poland-eu/">AI Sector</a> <a href="https://www.kg-legal.eu/data-centers/">Data Centers</a></td><td><a href="https://www.kg-legal.eu/regulatory-law-of-the-energy-sector-in-poland/">Energy Sector</a> <a href="https://www.kg-legal.eu/green-energy-law-renewable-energy-law/">Renewable Energy</a></td><td><a href="https://www.kg-legal.eu/medical-devices-including-medical-devices-law-under-combined-atmps/">Medical Devices</a> <a href="https://www.kg-legal.eu/food-law/">Food Law</a></td><td><a href="https://www.kg-legal.eu/international-divorces/">International Divorces</a> <a href="https://www.kg-legal.eu/international-family-law/">International Family Law</a></td></tr><tr><td><a href="https://www.kg-legal.eu/agreements-and-contracts/">Agreements &amp; Contracts</a> <a href="https://www.kg-legal.eu/contracts-in-the-international-trade-smart-contracts/">International Trade &amp; Smart Contracts</a></td><td><a href="https://www.kg-legal.eu/data-privacy-and-data-protection/">Data Privacy &amp; Protection</a> <a href="https://www.kg-legal.pl/cybersecurity/">Cybersecurity</a></td><td><a href="https://www.kg-legal.eu/biofuels-and-biocomponents/">Biofuels &amp; Biocomponents</a> <a href="https://www.kg-legal.eu/offshore-wind-farms/">Offshore Wind</a></td><td><a href="https://www.kg-legal.eu/art-market/">Art Market</a> <a href="https://www.kg-legal.eu/legal-services-in-fashion-law/">Fashion</a></td><td><a href="https://www.kg-legal.eu/cross-border-inheritance-matters/">Cross Border Inheritance</a> <a href="https://www.kg-legal.eu/immigration-law-business-immigration-polish-passport/">Immigration &amp; Polish Passports</a></td></tr><tr><td><a href="https://www.kg-legal.eu/offshore-companies-tax-optimization/">Offshore Companies &amp; Tax</a></td><td><a href="https://www.kg-legal.eu/distributed-ledger-technology-law/">Distributed Ledger Technology</a> <a href="https://www.kg-legal.eu/metaverse-and-web3-legal-environment/">Metaverse &amp; Web3</a></td><td><a href="https://www.kg-legal.eu/greenfield-in-poland/">Greenfield Investment</a> <a href="https://www.kg-legal.eu/kieltyka-gladkowski-provides-assistance-in-the-area-of-european-partnerships-in-horizon-europe-programme/">Horizon Europe</a></td><td><a href="https://www.kg-legal.pl/cross-border-cases-1/">Cross Border Practice</a> <a href="https://www.kg-legal.eu/customs-and-tariffs-support-for-international-traders-in-poland-and-eu/">Customs &amp; Tariffs</a></td><td><a href="https://www.kg-legal.eu/asset-tracing-in-poland-for-international-creditors/">Asset Tracing in Poland</a> <a href="https://www.kg-legal.eu/asset-tracing/">Asset Tracing</a> <a href="https://www.kg-legal.eu/business-investigations-private-detective-services/">Business Investigations</a></td></tr><tr><td><a href="https://www.kg-legal.eu/dissolution-and-liquidation-of-capital-companies/">Company Dissolution &amp; Liquidation</a> <a href="https://www.kg-legal.eu/cross-border-bankruptcy-in-poland/">Cross Border Bankruptcy</a></td><td><a href="https://www.kg-legal.eu/dual-use-technology-law/">Dual Use Technology</a> <a href="https://www.kg-legal.eu/drone-uas-law/">Drones &amp; UAS</a> <a href="https://www.kg-legal.eu/defence-and-space-sector/">Defence &amp; Space</a></td><td><a href="https://www.kg-legal.eu/industrial-micro-and-public-macro-infrastructure/">Infrastructure</a> <a href="https://www.kg-legal.eu/construction/">Construction</a> <a href="https://www.kg-legal.eu/public-private-partnerships/">Public Private Partnerships</a></td><td><a href="https://www.kg-legal.eu/sworn-certified-legal-translations-of-documents-and-contracts/">Sworn &amp; Certified Legal Translations</a></td><td><a href="https://www.kg-legal.eu/litigation-and-representation-of-international-clients-before-the-polish-courts/">Litigation in Polish Courts</a> <a href="https://www.kg-legal.eu/litigation-antitrust-and-competition-law/">Litigation &amp; Competition</a></td></tr></tbody></table></figure>



<p>Service directory: <a href="https://www.kg-legal.eu/services/">kg-legal.eu/services</a></p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/thuringia-meets-malopolska-kg-legal-kieltyka-gladkowski-at-the-business-meeting-with-minister-president-mario-voigt-at-solaris/">Thuringia Meets Małopolska: KG Legal KIELTYKA GLADKOWSKI at the Business Meeting with Minister-President Mario Voigt at SOLARIS</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/thuringia-meets-malopolska-kg-legal-kieltyka-gladkowski-at-the-business-meeting-with-minister-president-mario-voigt-at-solaris/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Paying Interest on Bad Code: Why Technical Debt Has Become a Legal Problemh</title>
		<link>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/technical-debt-and-legal-risk-gdpr-and-nis2-explained/</link>
					<comments>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/technical-debt-and-legal-risk-gdpr-and-nis2-explained/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Wed, 04 Nov 2026 11:27:57 +0000</pubDate>
				<category><![CDATA[IT, NEW TECHNOLOGIES, MEDIA AND COMMUNICATION TECHNOLOGY LAW]]></category>
		<category><![CDATA[AI Accountability]]></category>
		<category><![CDATA[Architecture Decision Records]]></category>
		<category><![CDATA[ASVS]]></category>
		<category><![CDATA[Automated Testing]]></category>
		<category><![CDATA[CI/CD]]></category>
		<category><![CDATA[cross border cases]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[Dynamic Application Security Testing]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[GDPR Article 32]]></category>
		<category><![CDATA[ISO/IEC 27001]]></category>
		<category><![CDATA[IT Governance]]></category>
		<category><![CDATA[IT Law]]></category>
		<category><![CDATA[KG Legal]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[Legacy Code]]></category>
		<category><![CDATA[Legacy Systems]]></category>
		<category><![CDATA[Legal Risk]]></category>
		<category><![CDATA[Management Liability]]></category>
		<category><![CDATA[NIS2]]></category>
		<category><![CDATA[OWASP]]></category>
		<category><![CDATA[Patch Management]]></category>
		<category><![CDATA[Poland]]></category>
		<category><![CDATA[Polish KSC Act]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Refactoring]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Secure Software Development]]></category>
		<category><![CDATA[Service Level Agreements]]></category>
		<category><![CDATA[Software Composition Analysis]]></category>
		<category><![CDATA[Software Documentation]]></category>
		<category><![CDATA[Software Maintenance]]></category>
		<category><![CDATA[Software Quality]]></category>
		<category><![CDATA[Software Supply Chain Security]]></category>
		<category><![CDATA[Static Application Security Testing]]></category>
		<category><![CDATA[Technical Debt]]></category>
		<category><![CDATA[Test-Driven Development]]></category>
		<category><![CDATA[Third-Party Dependencies]]></category>
		<category><![CDATA[Vulnerability Management]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8978</guid>

					<description><![CDATA[<p>Publication date: November 04, 2026 Technical debt, GDPR and NIS2 – how yesterday’s shortcuts turn into tomorrow’s liability Why technical debt arises Technical debt is a phenomenon that sooner or later affects almost every IT project. It consists in choosing a solution that is quicker to deliver but inferior in technical quality. A team usually [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/technical-debt-and-legal-risk-gdpr-and-nis2-explained/">Paying Interest on Bad Code: Why Technical Debt Has Become a Legal Problemh</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: November 04, 2026</mark></strong></p>



<p><em>Technical debt, GDPR and NIS2 – how yesterday’s shortcuts turn into tomorrow’s liability</em></p>



<h2 class="wp-block-heading">Why technical debt arises</h2>



<p>Technical debt is a phenomenon that sooner or later affects almost every IT project. It consists in choosing a solution that is quicker to deliver but inferior in technical quality. A team usually “takes out” this loan under pressure from the business side, for which the key metric is <strong>time-to-market</strong> – the sooner the product reaches the market, the better.</p>



<p>In the short term this brings a quick win, but in the future the company has to start paying the “interest”. It shows up as ever higher system maintenance costs, a slowdown in the pace of work, and the mounting frustration of developers who, instead of developing the product, must keep fixing the same defects over and over. Although the term “technical debt” appears nowhere in legislation, concepts such as <strong>due diligence</strong> and the <strong>adequacy of technical measures</strong> in practice force companies to keep that debt from spiralling out of control.</p>



<span id="more-8978"></span>



<h2 class="wp-block-heading">The forms that technological neglect takes</h2>



<p>Technical debt is not homogeneous; it accumulates in many places. One of the biggest problems is <strong>legacy code</strong> – code built on technologies that are no longer maintained. It often degenerates into so-called <strong>spaghetti code</strong>: a structure so tangled that a change in one place causes an unexpected failure in an entirely different part of the system.</p>



<p>Another barrier is the absence of automated tests, which forces the team into manual testing – where mistakes are easiest to make. Closely related is <strong>code duplication</strong>, that is, solving the same problem repeatedly in different parts of the application. Nor should the lack of documentation be forgotten, which gives rise to so-called <strong>tribal knowledge</strong>. When key employees leave, the organisation is left with a system that no one can operate or develop efficiently.</p>



<h2 class="wp-block-heading">The consequences for business and cybersecurity</h2>



<p>Technical debt is not merely an IT department problem – it strikes directly at the stability of the company. Outdated architecture leads to outages and performance degradation, which can result in breaches of <strong>SLA</strong> commitments and financial penalties. The greatest nightmare, however, are <strong>regressions</strong>: situations in which new features break functionality that previously worked correctly.</p>



<p>The most serious risks, though, are those to security. Failure to update components (<strong>third-party dependencies</strong>) exposes the company to <strong>zero-day</strong> attacks and to vulnerabilities catalogued in public <strong>CVE</strong> databases. Hackers routinely scan the internet for systems running old libraries for which security patches are no longer issued. Ignoring this problem is the simplest way to become an easy target.</p>



<h2 class="wp-block-heading">Technical debt under the GDPR and the “state of the art” principle</h2>



<p>The law today requires companies to take a proactive approach to risk. Under the <strong>GDPR</strong> (Article 32), controllers must implement measures that take account of the current <strong>state of the art</strong>. Using outdated encryption methods, or libraries that no longer receive updates, may amount to a breach of these provisions.</p>



<p>Technical debt also strikes at the principle of <strong>accountability</strong>. If, because of the poor state of its code, a company is unable to give effect efficiently to, say, the “right to be forgotten”, the supervisory authority may treat this as gross negligence. In the event of a data breach, the existence of substantial technical debt will be an aggravating circumstance – and may drastically increase the amount of the fine.</p>



<h2 class="wp-block-heading">Management board liability: NIS2 and the Polish KSC Act</h2>



<p>New regulations – the <strong>NIS2 Directive</strong> and the amended Polish <strong>Act on the National Cybersecurity System (KSC)</strong> implementing it, in force since 3 April 2026 – place responsibility for these matters directly on senior management. NIS2 puts strong emphasis on supply chain security and vulnerability management. If a system is so fragile that installing a patch risks bringing it down, the management board is caught in a trap: the law requires vulnerabilities to be patched, while the technical condition of the system makes that impossible.</p>



<p>Such omissions carry not only financial penalties but even a ban on holding managerial positions. Standards such as <strong>ISO/IEC 27001</strong>, <strong>ASVS</strong> and the <strong>OWASP</strong> guidelines are becoming the points of reference – ignoring them is treated as knowingly accepting an excessive level of risk.</p>



<h1 class="wp-block-heading">Strategies and prevention</h1>



<p>Managing technical debt does not mean halting all work; it means introducing healthy rules. Key among them is the <strong>boy scout rule</strong> – leave the code in a better state than you found it. It is also worth applying <strong>TDD (test-driven development)</strong>, that is, writing tests before the code, which builds a “safety net”.</p>



<p>To combat vulnerabilities, <strong>SCA</strong>-class tools that automatically monitor external packages are indispensable. <strong>CI/CD</strong> pipelines with built-in static (<strong>SAST</strong>) and dynamic (<strong>DAST</strong>) analysis should be the standard. To stop knowledge leaking out of the company, it is worth adopting a <strong>docs-as-code</strong> model (documentation kept together with the code) and maintaining architecture decision records (<strong>ADRs</strong>). In this way it is possible to build a system that is not only modern but, above all, secure and legally compliant.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/technical-debt-and-legal-risk-gdpr-and-nis2-explained/">Paying Interest on Bad Code: Why Technical Debt Has Become a Legal Problemh</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/it-new-technologies-media-and-communication-technology-law/technical-debt-and-legal-risk-gdpr-and-nis2-explained/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>CLIENT ALERT Dietary supplements market in Poland Amendments to food safety regulations &#124; May 2026</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Wed, 08 Jul 2026 11:04:24 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[Advertising Law]]></category>
		<category><![CDATA[Business Law]]></category>
		<category><![CDATA[CEE]]></category>
		<category><![CDATA[Central and Eastern Europe]]></category>
		<category><![CDATA[Client Alert]]></category>
		<category><![CDATA[Commercial Law]]></category>
		<category><![CDATA[Compliance Management]]></category>
		<category><![CDATA[Consumer Health]]></category>
		<category><![CDATA[CONSUMER PROTECTION]]></category>
		<category><![CDATA[Corporate Compliance]]></category>
		<category><![CDATA[corporate law]]></category>
		<category><![CDATA[Cross-Border Business]]></category>
		<category><![CDATA[Dietary Supplements]]></category>
		<category><![CDATA[Distributors]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[e-commerce]]></category>
		<category><![CDATA[e-Sanepid]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[European Regulatory Law]]></category>
		<category><![CDATA[European Union Law]]></category>
		<category><![CDATA[Food and Nutrition Safety Act]]></category>
		<category><![CDATA[Food Business]]></category>
		<category><![CDATA[food industry]]></category>
		<category><![CDATA[Food Law]]></category>
		<category><![CDATA[Food Regulation]]></category>
		<category><![CDATA[Food Safety]]></category>
		<category><![CDATA[Food Supplements]]></category>
		<category><![CDATA[General Counsel]]></category>
		<category><![CDATA[GIS]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Importers]]></category>
		<category><![CDATA[In-House Counsel]]></category>
		<category><![CDATA[International Business]]></category>
		<category><![CDATA[International Lawyers]]></category>
		<category><![CDATA[international trade]]></category>
		<category><![CDATA[KG Legal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[Law Firm]]></category>
		<category><![CDATA[Legal Compliance]]></category>
		<category><![CDATA[Legal Insights]]></category>
		<category><![CDATA[Legal Risk]]></category>
		<category><![CDATA[Legal Update]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<category><![CDATA[Manufacturers]]></category>
		<category><![CDATA[Market Entry]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[Online Retail]]></category>
		<category><![CDATA[Poland]]></category>
		<category><![CDATA[Poland Food Law]]></category>
		<category><![CDATA[Polish Food Law]]></category>
		<category><![CDATA[Product Compliance]]></category>
		<category><![CDATA[Product Safety]]></category>
		<category><![CDATA[Regulatory Affairs]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Regulatory Law]]></category>
		<category><![CDATA[Risk Management]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8825</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 The draft Act of April 13, 2026, amending the Act on Food and Nutrition Safety will enter into force six months after its publication. The new regulations primarily impact producers, importers, distributors, and sellers of dietary supplements &#8211; both in traditional and online channels. Below, we present the real changes [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/">CLIENT ALERT Dietary supplements market in Poland Amendments to food safety regulations | May 2026</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><em>The draft Act of April 13, 2026, amending the Act on Food and Nutrition Safety will enter into force six months after its publication. The new regulations primarily impact producers, importers, distributors, and sellers of dietary supplements &#8211; both in traditional and online channels. Below, we present the real changes to your business.</em></td></tr></tbody></table></figure>



<span id="more-8825"></span>



<h1 class="wp-block-heading">1. Reports only via e-Sanepid</h1>



<p>Every dietary supplement introduced to the market for the first time must be reported to the Chief Sanitary Inspector (GIS). Until now, various forms were acceptable &#8211; paper or electronic, with a handwritten or electronic signature. After the amendment comes into effect, the only acceptable method will be the e-Sanepid platform.</p>



<p>What does this mean in practice?</p>



<ul class="wp-block-list">
<li>It is necessary for each person submitting notifications to have a qualified electronic signature or a trusted profile.</li>



<li>All communication with sanitary inspection bodies &#8211; letters, decisions, and confirmations &#8211; will be handled through the platform account. The moment of notification submission will be clearly confirmed with an official receipt, eliminating disputes over the deadline.</li>



<li>Companies that have previously used paper forms or traditional correspondence must immediately switch to the new channel and ensure appropriate employee training.</li>
</ul>



<p>The change also concerns the timing of the notification obligation: the previous option to notify the Chief Sanitary Inspectorate (GIS) at the stage of intended product introduction is no longer available. The obligation now arises at the time of actual introduction to the market.</p>



<h1 class="wp-block-heading">2. Strict deadlines and automatic presumption of irregularities</h1>



<p>The amendment introduces a completely new mechanism for conducting investigations. This change has the greatest potential to surprise companies without effective internal compliance procedures.</p>



<h2 class="wp-block-heading">How does the new mechanism work?</h2>



<p>If the Chief Sanitary Inspectorate initiates an investigation and requests the entity to submit a scientific opinion, the company has exactly 14 days to submit an application to an accredited scientific unit – at the same time forwarding a copy of it to the Chief Sanitary Inspectorate.</p>



<figure class="wp-block-table"><table class="has-vivid-cyan-blue-color has-luminous-vivid-amber-background-color has-text-color has-background has-link-color has-fixed-layout"><tbody><tr><td><strong>Step</strong></td><td><strong>What&#8217;s going on</strong></td></tr><tr><td><strong>14 days</strong></td><td>Deadline for submitting an application for a scientific opinion to a scientific unit (from the date of delivery of the request by GIS)</td></tr><tr><td><strong>6 months</strong></td><td>Maximum time for a scientific unit to issue an opinion</td></tr><tr><td><strong>Up to 12 months</strong></td><td>Possible extension of the deadline by the entity if the case is complex</td></tr><tr><td><strong>Failure to meet 14 days</strong></td><td>Automatic presumption that the product is incorrectly classified and does not meet the requirements &#8211; GIS ends the proceedings to the detriment of the entity</td></tr></tbody></table></figure>



<p>The mechanism for presuming irregularities is a significant innovation. Previously, a company&#8217;s inaction during the proceedings did not automatically result in any legal consequences &#8211; the proceedings could drag on for years. Following the amendment, any failure to meet the 14-day deadline will lead to direct negative consequences, regardless of whether the product is safe.</p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>The ban on re-registration – an important trap</strong></td></tr><tr><td>Once the investigation is complete, the entity cannot submit a new notification for a product with the same qualitative and quantitative composition. If the company withdraws its notification during the investigation, this prohibition is indefinite. In such cases, changing the composition may be the only way to return to the market.</td></tr></tbody></table></figure>



<h1 class="wp-block-heading">3. Advertising without reporting? A fine of nearly one million zlotys</h1>



<p>This change directly impacts brands engaging in active digital marketing. Previously, advertising or presenting a dietary supplement without prior notification to the Chief Sanitary Inspectorate (GIS) was punishable by a fine (a misdemeanor). Following the amendment, this becomes grounds for imposing an administrative fine &#8211; with new, significantly higher penalties.</p>



<h2 class="wp-block-heading">What exactly is prohibited?</h2>



<p>The amendment penalizes not only the sale of a supplement without reporting it to the Chief Sanitary Inspectorate (GIS), but also the mere advertising or presentation of it if the notification has not been effectively submitted. In other words:</p>



<ul class="wp-block-list">
<li>Sponsored post on Instagram or Facebook promoting a new supplement before notification = grounds for an administrative penalty.</li>



<li>Product page in the online store visible to the public before successful reporting to GIS = risk of infringement.</li>



<li>Promotional materials sent to wholesalers or distributors before GIS is notified = potential infringement.</li>



<li>Influencer marketing initiated before the date of effective notification = liability on the part of the entity commissioning the campaign.</li>
</ul>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>Key: What is a &#8220;successful report&#8221;?</strong></td></tr><tr><td>The notification is effectively submitted when the company receives official confirmation of receipt from the e-Sanepid platform. Simply submitting the form isn&#8217;t enough &#8211; confirmation is what counts. These dates can differ by several days or more. Every marketing campaign should be planned with this time buffer in mind.</td></tr></tbody></table></figure>



<h2 class="wp-block-heading">Prohibition on suggesting medicinal properties &#8211; wider scope</h2>



<p>The amendment expands liability for violations of advertising requirements from labeling to the entire marketing message. Previously, sanctions primarily covered incorrect packaging labeling. Following the amendment, a company is responsible for every communication channel &#8211; online advertising, point-of-sale materials, newsletters, or YouTube videos &#8211; if the message suggests that a varied diet does not provide sufficient nutrients, or if a supplement is presented as a medicinal product.</p>



<h1 class="wp-block-heading">4. Public register &#8211; the company&#8217;s reputation under public scrutiny</h1>



<p>The Chief Sanitary Inspectorate (GIS) has maintained a register of dietary supplements before, but the amendment will significantly expand its scope and availability. The data will be published on the e-Sanepid platform and will include:</p>



<ul class="wp-block-list">
<li>the name of the product and its qualitative composition (without quantitative data &#8211; the recipe remains protected),</li>



<li>product qualification proposed by the entity,</li>



<li>information about the initiation or ongoing investigation,</li>



<li>data on the detection of a prohibited ingredient.</li>
</ul>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>Reputational risk before final decision</strong></td></tr><tr><td>Information about the initiation of an investigation will appear in the public register immediately &#8211; not after the proceedings have concluded. Consumers and competitors will have access to this information before the Chief Sanitary Inspectorate issues any ruling. Even if the proceedings end favorably for the company, the registry record could impact brand perception.</td></tr></tbody></table></figure>



<h1 class="wp-block-heading">5. Fines &#8211; increase by over 330%</h1>



<p>The maximum administrative fine for violating food safety regulations is increasing from 30 to 100 times the average monthly salary. At the current salary level, this means:</p>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>&nbsp;</td><td><strong>Before the amendment</strong></td><td><strong>After the amendment</strong></td></tr><tr><td><strong>Multiplier</strong></td><td>30×</td><td><strong>100×</strong></td></tr><tr><td><strong>Maximum penalty</strong></td><td>approx. PLN 245,000</td><td><strong>approx. PLN 818,000</strong></td></tr></tbody></table></figure>



<p>The new penalties are imposed administratively (not as fiscal or misdemeanor offenses), which means faster proceedings and no need to prove intentional guilt. A mere finding of a violation is sufficient. The increased level of sanctions has a real deterrent effect, especially for companies with turnover in the tens of millions of zlotys.</p>



<h1 class="wp-block-heading">The biggest risks &#8211; a practical overview</h1>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>Risk area</strong></td><td><strong>Triggering situation</strong></td><td><strong>Consequence</strong></td></tr><tr><td><strong>Advertising before submission</strong></td><td>Launch of the campaign on social media before the official confirmation of receipt of the notification by the Chief Sanitary Inspectorate</td><td>Fine up to approximately PLN 818,000</td></tr><tr><td><strong>Exceeding the 14-day deadline</strong></td><td>No application submitted to the scientific unit within 14 days of the request by the Chief Sanitary Inspectorate</td><td>Automatic presumption of product irregularity; termination of proceedings to the detriment of the entity</td></tr><tr><td><strong>Errors in the product description on the website</strong></td><td>Content suggesting medicinal properties or claiming that a diet without a supplement is insufficient</td><td>Fine of up to approximately PLN 818,000; risk of product recall</td></tr><tr><td><strong>Publicity of the proceedings</strong></td><td>Initiation of explanatory proceedings by GIS</td><td>Immediate publication of information in the public register &#8211; reputational damage before resolution</td></tr><tr><td><strong>Sale without notification</strong></td><td>Distribution to wholesalers or stores before effective notification of the Chief Sanitary Inspectorate</td><td>A fine of up to approximately PLN 818,000; possible ban on further trading</td></tr><tr><td><strong>No trusted profile/signature</strong></td><td>The employees responsible for reporting do not have the required qualifications</td><td>Notification submitted ineffectively &#8211; risk of sanctions as for failure to notify</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>What is worth doing before the regulations come into force?</strong></td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>1. Register on the e-Sanepid platform</strong></td></tr><tr><td>Ensure that at least two people in your company have a qualified electronic signature or an active trusted profile. Register a company account on e-Sanepid before the law comes into effect and complete a test application. A lack of technical readiness on the date the regulations come into effect could prevent you from legally introducing new products to the market.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>2. Audit current submissions and the new product calendar</strong></td></tr><tr><td>Check that all products in your offer have successfully submitted notifications to the Chief Sanitary Inspectorate. For products planned for launch in the coming months, submit notifications well in advance of the planned sale date or marketing campaign. Take into account the waiting time for official confirmation of receipt.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>3. Implement a procedure for monitoring deadlines in explanatory proceedings</strong></td></tr><tr><td>Designate a person responsible for receiving correspondence from the e-Sanepid platform and immediately forwarding documents to legal or compliance services. The 14-day deadline for submitting a request for a scientific opinion is short—missing it automatically creates a presumption of irregularities. It&#8217;s worth identifying accredited scientific institutions now with which the company could quickly establish cooperation if proceedings are initiated.</td></tr></tbody></table></figure>



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><strong>4. Verify all marketing materials – websites, social media, product descriptions</strong></td></tr><tr><td>Analyze the content on your website, online store, social media profiles and sales materials for:</td></tr><tr><td>suggestions for medicinal or therapeutic properties of supplements,</td></tr><tr><td>information suggesting that a normal diet does not provide adequate nutrients,</td></tr><tr><td>promoting products for which the GIS notification has not yet been successfully submitted.</td></tr><tr><td>Influencer marketing campaigns deserve special attention – messages created by third parties still place the responsibility on the company commissioning the campaign.</td></tr></tbody></table></figure>



<figure class="wp-block-table">
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>5. Monitor the GIS register and respond to information about proceedings</strong></td>
</tr>
<tr>
<td>Once the expanded SEPIS register is launched, regularly check the status of your products. If you receive information about the initiation of an investigation, act immediately. Inaction at this stage can lead to automatic assumptions of irregularities and reputational damage that will be publicly visible throughout the proceedings.</td>
</tr>
</tbody>
</table>
</figure>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/">CLIENT ALERT Dietary supplements market in Poland Amendments to food safety regulations | May 2026</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/client-alert-dietary-supplements-market-in-polandamendments-to-food-safety-regulations-may-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>A Major Milestone for KG Legal&#8217;s Data, AI &#038; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</title>
		<link>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/</link>
					<comments>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 19:32:01 +0000</pubDate>
				<category><![CDATA[KG LEGAL NEWS]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[AI Compliance]]></category>
		<category><![CDATA[AI Regulation]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[CEE]]></category>
		<category><![CDATA[Corporate Counsel]]></category>
		<category><![CDATA[Cross Border Business]]></category>
		<category><![CDATA[Cross Border Legal Services]]></category>
		<category><![CDATA[Cyber Compliance]]></category>
		<category><![CDATA[Cyber Law]]></category>
		<category><![CDATA[Data Governance]]></category>
		<category><![CDATA[Data Privacy]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[DataGuidance]]></category>
		<category><![CDATA[Digital Compliance]]></category>
		<category><![CDATA[Digital Economy]]></category>
		<category><![CDATA[Digital Law]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[Emerging Technologies]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[European Law]]></category>
		<category><![CDATA[Foreign Investors]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[GDPR Compliance]]></category>
		<category><![CDATA[GDPR Poland]]></category>
		<category><![CDATA[General Counsel]]></category>
		<category><![CDATA[Global Law]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Healthcare Regulation]]></category>
		<category><![CDATA[In House Counsel]]></category>
		<category><![CDATA[International Law Firm]]></category>
		<category><![CDATA[International Legal Services]]></category>
		<category><![CDATA[Invest in Poland]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[Law Firm Poland]]></category>
		<category><![CDATA[Legal Innovation]]></category>
		<category><![CDATA[Legal Tech]]></category>
		<category><![CDATA[Legal Thought Leadership]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[NIS2]]></category>
		<category><![CDATA[OneTrust]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Poland Law]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Polish Law Firm]]></category>
		<category><![CDATA[Privacy Law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Technology Law]]></category>
		<category><![CDATA[Technology Transactions]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8822</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 We are delighted to share an important milestone in the continued development of KG Legal&#8217;s Data, AI &#38; Cybersecurity Desk. It has been a great honour to serve as the exclusive expert contributors for Poland to the OneTrust DataGuidance Privacy Overview – Poland, one of the world&#8217;s leading professional legal [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/">A Major Milestone for KG Legal&#8217;s Data, AI &amp; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<p>We are delighted to share an important milestone in the continued development of <strong>KG Legal&#8217;s Data, AI &amp; Cybersecurity Desk</strong>.</p>



<figure class="wp-block-image size-full"><img decoding="async" width="1000" height="1000" src="https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge.png" alt="" class="wp-image-8823" srcset="https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge.png 1000w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-300x300.png 300w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-150x150.png 150w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-768x768.png 768w" sizes="(max-width: 1000px) 100vw, 1000px" /></figure>



<p>It has been a great honour to serve as the <strong>exclusive expert contributors for Poland</strong> to the <strong>OneTrust DataGuidance Privacy Overview – Poland</strong>, one of the world&#8217;s leading professional legal compliance resources relied upon by in-house counsel, privacy professionals, compliance officers, multinational organisations and technology companies operating across multiple jurisdictions.</p>



<span id="more-8822"></span>



<p>Preparing this contribution was a long-term project that required several months of intensive legal analysis, research and editorial work. Our objective was not simply to describe the application of the GDPR in Poland. Instead, we sought to create a practical and comprehensive guide reflecting the significant transformation of the Polish regulatory landscape that has taken place in recent years as a result of new European legislation and its implementation into Polish law.</p>



<p>The publication therefore extends far beyond a traditional overview of Polish data protection law. It examines the interaction between privacy, digital regulation, cybersecurity and artificial intelligence, providing readers with practical guidance on the most important legal developments affecting organisations operating in Poland.</p>



<p>Our contribution discusses, among other things:</p>



<ul class="wp-block-list">
<li>the practical application of the GDPR within the Polish legal system;</li>



<li>the powers and regulatory practice of the Polish supervisory authority for personal data protection;</li>



<li>employee monitoring and workplace privacy;</li>



<li>cookies, consent mechanisms and online tracking technologies;</li>



<li>electronic communications and direct marketing requirements;</li>



<li>international data transfers;</li>



<li>personal data breaches and notification obligations;</li>



<li>practical compliance with Polish privacy legislation;</li>



<li>cybersecurity-related regulatory developments;</li>



<li>the growing interaction between data protection and artificial intelligence governance.</li>
</ul>



<p>A particularly important aspect of this work was addressing the rapidly evolving legislative environment. During the last few years, Poland has experienced substantial regulatory changes resulting from the implementation of numerous European legal instruments and the entry into force of directly applicable EU regulations that significantly affect organisations processing personal data.</p>



<p>Accordingly, the publication takes into account the practical implications of the evolving European digital regulatory framework, including the interaction between the GDPR and newer legal instruments governing digital services, artificial intelligence, cybersecurity and data governance. The analysis also reflects the impact of the AI regulatory framework, developments concerning data governance and electronic communications, as well as the increasingly interconnected compliance obligations facing businesses operating in today&#8217;s digital economy.</p>



<p>Rather than presenting legislation in isolation, the publication adopts a practical, compliance-oriented perspective. It combines:</p>



<ul class="wp-block-list">
<li>the GDPR and Polish implementing legislation;</li>



<li>guidance issued by the European Data Protection Board (EDPB);</li>



<li>the jurisprudence of the Court of Justice of the European Union;</li>



<li>decisions and regulatory guidance published by the Polish Personal Data Protection Office (UODO);</li>



<li>recent Polish legislative developments and market practice.</li>
</ul>



<p>Our ambition was to create a resource that would assist both international and domestic organisations in navigating one of the fastest-changing areas of European regulation, where privacy law increasingly intersects with cybersecurity, AI governance, digital platforms, online communications and emerging technologies.</p>



<p>The contribution was prepared by <strong>Małgorzata Kiełtyka</strong> and <strong>Jakub Gładkowski</strong>, whose combined experience covers complex cross-border advisory work in data protection, artificial intelligence, life sciences, healthcare, technology law, cybersecurity, intellectual property and regulatory compliance.</p>



<p><a href="https://www.dataguidance.com/experts-directory/Jakub_G%C5%82adkowski" target="_blank" rel="noreferrer noopener">https://www.dataguidance.com/experts-directory/Jakub_G%C5%82adkowski</a></p>



<p><a href="https://www.dataguidance.com/experts-directory/Malgorzata_Kieltyka">https://www.dataguidance.com/experts-directory/Malgorzata_Kieltyka</a></p>



<p>For many years, Małgorzata Kiełtyka has advised international companies on GDPR compliance, healthcare regulation, AI governance, technology transactions and cross-border regulatory matters. Her practice combines strategic legal advice with practical implementation of compliance frameworks for multinational businesses operating in highly regulated sectors.</p>



<p>Jakub Gładkowski focuses on data protection, digital regulation, cybersecurity, intellectual property, IT law and emerging technologies. His practice includes advising innovative businesses on regulatory compliance, digital transformation projects and the implementation of European technology legislation affecting both public and private sector organisations.</p>



<p>Being entrusted with preparing Poland&#8217;s national contribution to OneTrust DataGuidance represents an important recognition of our team&#8217;s expertise and international standing. We are particularly proud that this publication reflects not only our experience in privacy law, but also our broader interdisciplinary approach, integrating data protection with AI regulation, cybersecurity, digital compliance and technology law.</p>



<p>We sincerely thank the editorial team at <strong>OneTrust DataGuidance</strong> for their confidence in our expertise and for the opportunity to contribute to a publication that supports legal and compliance professionals around the world.</p>



<p>For KG Legal, this publication marks another significant milestone in the continued growth of our <strong>Data, AI &amp; Cybersecurity Desk</strong> and reinforces our commitment to delivering practical, business-oriented legal advice at the intersection of privacy, technology and innovation.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/">A Major Milestone for KG Legal&#8217;s Data, AI &amp; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 18:09:37 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[Administrative Law]]></category>
		<category><![CDATA[Advertising Law]]></category>
		<category><![CDATA[Compliance Risk]]></category>
		<category><![CDATA[CONSUMER PROTECTION]]></category>
		<category><![CDATA[Corporate Compliance]]></category>
		<category><![CDATA[Cross Border Business]]></category>
		<category><![CDATA[Digital Compliance]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[EU Food Regulation]]></category>
		<category><![CDATA[eu regulation]]></category>
		<category><![CDATA[Food Law]]></category>
		<category><![CDATA[Food Safety]]></category>
		<category><![CDATA[GIS Poland]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[International Law Firms]]></category>
		<category><![CDATA[Invest in Poland]]></category>
		<category><![CDATA[Legal Services Poland]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[Life Sciences Regulation]]></category>
		<category><![CDATA[Marketing Compliance]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Poland Law]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Sanitary Regulation]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8807</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 The Polish dietary supplements market is facing the most significant regulatory overhaul in years. The draft amendment to the Act on Food and Nutrition Safety and the Act on the State Sanitary Inspectorate introduces a series of far-reaching changes that will substantially alter the way supplements are notified, monitored, advertised, [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/">Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<p>The Polish dietary supplements market is facing the most significant regulatory overhaul in years. The draft amendment to the Act on Food and Nutrition Safety and the Act on the State Sanitary Inspectorate introduces a series of far-reaching changes that will substantially alter the way supplements are notified, monitored, advertised, and supervised in Poland. While the reform does not formally introduce a pre-market authorization system, it undeniably strengthens the position of regulatory authorities and increases the compliance burden imposed on businesses operating in the sector.</p>



<span id="more-8807"></span>



<p id="ember2883">The amendment, expected to enter into force six months after publication, reflects both domestic concerns regarding the rapid expansion of the supplements market and the broader European trend toward stricter food safety oversight. For manufacturers, importers, distributors, and marketing agencies, the proposed changes may require a complete reassessment of internal procedures, legal risk management, and commercial strategy.</p>



<p id="ember2884">The reform arrives at a time when the Polish dietary supplements market continues to expand at an exceptional pace. Poland has become one of the largest supplement consumers in the European Union, both in terms of total market value and per capita spending. According to market estimates, the sector exceeded PLN 7 billion in value in 2024 and is expected to continue growing steadily over the coming years. The scale of the market alone has become a challenge for regulators. Between 2017 and 2020, more than 62,000 supplement notifications were submitted to the Chief Sanitary Inspectorate (GIS), while the number of products listed in official registers exceeded 29,000.</p>



<p id="ember2885">At the same time, authorities increasingly pointed to systemic weaknesses in the existing framework. Under the current rules, a business may place a dietary supplement on the market immediately after submitting a notification to GIS, even if doubts exist regarding the product’s composition or classification. The authorities may initiate explanatory proceedings, but the product can still remain commercially available during the investigation. In practice, this system has often been criticized for providing insufficient preventive control and allowing potentially problematic products to circulate before any meaningful assessment takes place.</p>



<p id="ember2886">Another major concern involved the widespread use of aggressive advertising strategies. For years, the dietary supplements industry has been accused of blurring the line between supplements and medicinal products. Many advertisements indirectly suggested therapeutic effects or implied that supplements could substitute proper medical treatment or balanced nutrition. Regulators and pharmaceutical companies repeatedly argued that existing penalties were too low to deter large market participants from engaging in questionable promotional practices.</p>



<p id="ember2887">The lack of a centralized digital supervision system also contributed to inefficiencies. The notification process relied partly on outdated administrative mechanisms, resulting in difficulties with document verification, inconsistent communication, and lengthy proceedings. The new amendment seeks to address these concerns through digitalization, stricter procedural obligations, and substantially higher financial sanctions.</p>



<p id="ember2888">One of the most visible changes introduced by the reform is the mandatory use of the e-Sanepid platform for all supplement notifications. Until now, notifications could be submitted either electronically or in paper form, and businesses had some flexibility regarding the form and timing of submission. Under the new rules, however, the process becomes fully digitized. Notifications will only be accepted through the e-Sanepid system and will require either a qualified electronic signature or a trusted electronic profile.</p>



<p id="ember2889">This change may appear largely technical at first glance, but in reality it significantly increases the formalization of the entire notification process. For large companies with developed compliance departments, adapting to electronic communication systems is unlikely to create serious difficulties. Smaller businesses, however, may face operational and financial challenges connected with digital authentication tools, procedural monitoring, and document management requirements.</p>



<p id="ember2890">The amendment also changes the moment at which the notification obligation arises. Previously, the law referred both to products already introduced to the market and those merely intended for future introduction. The new wording removes the reference to “intended introduction,” meaning that the obligation will arise only once the product is actually being placed on the market. Although this clarification simplifies the legal interpretation of the obligation, it also narrows the flexibility businesses previously enjoyed when planning product launches.</p>



<p id="ember2891">Perhaps the most consequential aspect of the reform concerns explanatory proceedings and scientific opinions. Under the current framework, businesses could effectively delay proceedings indefinitely by postponing the submission of required scientific documentation. While the law imposed certain deadlines on the authorities themselves, it did not establish sufficiently strict obligations for the notifying entity. This created situations where proceedings remained unresolved for years, significantly limiting the effectiveness of supervision.</p>



<p id="ember2892">The amendment introduces a much stricter procedural regime. Once GIS requests a scientific opinion regarding a product’s classification or compliance, the business will have only 14 days to submit an application to a scientific institution or to the President of the Office for Registration of Medicinal Products. Furthermore, the scientific opinion itself must generally be issued within six months, with an absolute maximum period of twelve months in exceptional cases.</p>



<p id="ember2893">The most significant innovation is the introduction of a legal presumption against the entrepreneur. If the entity fails to submit the application for an opinion within the required 14-day period, the law will automatically presume that the proposed classification of the product is incorrect and that the product does not meet the requirements applicable to its category. In practical terms, procedural inactivity itself may lead to negative legal consequences.</p>



<p id="ember2894">This fundamentally changes the balance between businesses and regulatory authorities. Previously, delaying the process often worked in favor of companies by allowing products to remain on the market while proceedings continued. Under the new rules, inaction may immediately weaken the entrepreneur’s legal position. Businesses will therefore need to implement much stricter internal monitoring systems to ensure compliance with procedural deadlines.</p>



<p id="ember2895">The amendment additionally prohibits businesses from circumventing the procedure by repeatedly submitting notifications for identical products. Once proceedings are initiated, companies will no longer be able to submit another notification concerning a product with the same qualitative and quantitative composition. Similarly, withdrawing a notification will not allow the entrepreneur to restart the process with the same formula at a later stage. These restrictions are intended to eliminate procedural abuse and prevent companies from avoiding regulatory scrutiny through repeated filings.</p>



<p id="ember2896">Another major reform concerns transparency and the expansion of the public product register maintained within the SEPIS system. The current register already contains certain information regarding notified products, but the scope of publicly available data remains relatively limited. The new system significantly broadens the amount of information accessible to consumers and competitors alike.</p>



<p id="ember2897">Under the amendment, the register will include the product name, form of the product, qualitative composition, information regarding active substances, details concerning explanatory proceedings, and information about prohibited ingredients. Although quantitative composition data and certain identifying information regarding the reporting entity will remain confidential, the reform nevertheless represents a substantial increase in market transparency.</p>



<p id="ember2898">From the consumer protection perspective, this may be viewed as a positive development. Consumers will gain easier access to information about supplement composition and regulatory status, potentially allowing for more informed purchasing decisions. However, from the business perspective, the new transparency rules create considerable reputational risks. Information regarding ongoing explanatory proceedings may become publicly visible long before any final administrative decision is issued. As a result, companies may face reputational damage even in situations where no violation is ultimately confirmed.</p>



<p id="ember2899">The reform also updates the broader inspection framework to align Polish law with Regulation (EU) 2017/625 on official controls. Although the regulation has already been directly applicable across the European Union since 2019, several references in Polish legislation still pointed to repealed EU acts. The amendment therefore modernizes the legal terminology and adapts national provisions to the currently binding European framework.</p>



<p id="ember2900">Importantly, however, the changes do not significantly expand the substantive powers of sanitary authorities. The amendment primarily introduces terminological adjustments, extending references from “official food controls” to “official controls and other official activities.” Sanitary authorities will continue to possess extensive powers during inspections, including access to facilities, examination of production processes and documentation, and collection of samples for laboratory testing.</p>



<p id="ember2901">The reform does, however, expand the situations in which businesses must bear the costs of inspections and administrative activities. In addition to existing obligations related to violations, follow-up inspections, and border sanitary controls, businesses will now also be required to cover costs associated with official activities performed at their own request, such as the issuance of certain documents. While this change may appear relatively modest compared to other parts of the reform, it nevertheless contributes to the overall increase in operational costs for market participants.</p>



<p id="ember2902">One of the most controversial elements of the amendment concerns advertising and marketing practices. The reform significantly broadens the scope of administrative liability related to the promotion and presentation of dietary supplements. Previously, penalties focused primarily on incorrect product labeling. Under the new rules, liability will explicitly extend to advertising, online promotion, social media activities, and the overall presentation of products.</p>



<p id="ember2903">Most importantly, the amendment introduces severe sanctions for advertising or presenting a supplement before notifying GIS. This is likely to have a major impact on digital marketing strategies commonly used in the supplements industry. Influencer campaigns, online pre-launch promotions, teaser advertisements, and social media product announcements may all potentially fall within the scope of the new sanctions if conducted before formal notification.</p>



<p id="ember2904">The amendment also reinforces existing prohibitions against suggesting that a balanced diet cannot provide sufficient nutrients or implying medicinal properties of supplements. Although these prohibitions already existed under current law, the reform significantly strengthens enforcement mechanisms by attaching much higher financial penalties to violations.</p>



<p id="ember2905">Indeed, the increase in administrative penalties represents one of the most dramatic aspects of the reform. Under the current framework, the maximum administrative fine generally amounts to thirty times the average monthly salary. The amendment raises this threshold to one hundred times the average salary, increasing potential penalties by more than 330 percent.</p>



<p id="ember2906">Based on current economic indicators, maximum fines could exceed PLN 800,000. Such amounts are clearly intended to function as genuinely deterrent sanctions rather than symbolic administrative measures. For large corporations with extensive marketing operations, these penalties may significantly alter risk calculations related to aggressive advertising or borderline compliance practices.</p>



<p id="ember2907">For businesses operating in the supplements sector, the cumulative impact of these changes may be substantial. Compliance costs are likely to increase considerably. Companies may need to invest in legal advisory services, digital infrastructure, scientific assessments, employee training, and enhanced compliance monitoring systems. Marketing departments in particular will face increased scrutiny and will need to carefully verify advertising content before publication.</p>



<p id="ember2908">The reform may also contribute to market consolidation. Large, well-established companies are generally better positioned to absorb increased compliance costs and adapt to stricter regulatory requirements. Smaller businesses, startups, and niche supplement brands may struggle with the financial and administrative burden created by the new framework. As a result, the amendment could unintentionally reduce market diversity and strengthen the competitive position of major industry players.</p>



<p id="ember2909">From the perspective of public authorities, the reform aims to improve the efficiency and credibility of food safety supervision. Digitalization through e-Sanepid and SEPIS is expected to accelerate administrative processes, improve data analysis capabilities, and strengthen market oversight. The introduction of strict procedural deadlines should also reduce the risk of excessively lengthy proceedings and administrative disputes.</p>



<p id="ember2910">At the same time, the implementation of these systems will require significant investments in technological infrastructure and administrative capacity. The effectiveness of the reform will therefore depend not only on the wording of the legislation itself, but also on the practical ability of GIS and related institutions to manage the new digital environment efficiently.</p>



<p id="ember2911">Ultimately, the amendment does not formally transform dietary supplements into products requiring prior authorization before market entry. Businesses will still be able to introduce supplements through a notification-based system rather than a licensing procedure. Nevertheless, the practical reality of operating in the sector is likely to change considerably.</p>



<p id="ember2912">The reform substantially increases the procedural obligations imposed on businesses, strengthens enforcement tools available to authorities, raises financial exposure connected with non-compliance, and introduces far greater transparency into the market. While these changes may improve consumer protection and market oversight, they also create new operational and reputational risks for entrepreneurs.</p>



<p id="ember2913">For companies active in the supplements industry, the coming months may therefore become a critical period of preparation. Businesses that fail to adapt quickly to the new regulatory environment may face not only financial penalties, but also significant disruptions to their commercial operations and marketing strategies.</p>
<p> </p>


<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/">Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Representatives of our law firm KG LEGAL KIEŁTYKA GŁADKOWSKI will take part in the Data Science Summit AI Edition 2026 – one of the largest events dedicated to artificial intelligence in Central and Eastern Europe</title>
		<link>https://www.kg-legal.eu/info/kg-legal-news/representatives-of-our-law-firm-kg-legal-kieltyka-gladkowski-will-take-part-in-the-data-science-summit-ai-edition-2026-one-of-the-largest-events-dedicated-to-artificial-intelligence-in-centr/</link>
					<comments>https://www.kg-legal.eu/info/kg-legal-news/representatives-of-our-law-firm-kg-legal-kieltyka-gladkowski-will-take-part-in-the-data-science-summit-ai-edition-2026-one-of-the-largest-events-dedicated-to-artificial-intelligence-in-centr/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Thu, 18 Jun 2026 10:22:15 +0000</pubDate>
				<category><![CDATA[KG LEGAL NEWS]]></category>
		<category><![CDATA[AIEdition2026]]></category>
		<category><![CDATA[ArtificialIntelligence]]></category>
		<category><![CDATA[DataScienceSummit]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[KG Legal]]></category>
		<category><![CDATA[MachineLearning]]></category>
		<category><![CDATA[ModelDistillation]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[WARSAW]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8801</guid>

					<description><![CDATA[<p>Publication date: June 18, 2026 On June 19, 2026, representatives of our law firm will participate in the Data Science Summit AI Edition 2026, which will be held at the Palace of Culture and Science in Warsaw. For many years, the event has been one of the most important technology conferences in Central and Eastern [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/representatives-of-our-law-firm-kg-legal-kieltyka-gladkowski-will-take-part-in-the-data-science-summit-ai-edition-2026-one-of-the-largest-events-dedicated-to-artificial-intelligence-in-centr/">Representatives of our law firm KG LEGAL KIEŁTYKA GŁADKOWSKI will take part in the Data Science Summit AI Edition 2026 – one of the largest events dedicated to artificial intelligence in Central and Eastern Europe</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: June 18, 2026</mark></strong></p>



<p>On June 19, 2026, representatives of our law firm will participate in the <strong>Data Science Summit AI Edition 2026</strong>, which will be held at the Palace of Culture and Science in Warsaw. For many years, the event has been one of the most important technology conferences in Central and Eastern Europe, bringing together specialists responsible for the development and implementation of the most advanced solutions based on artificial intelligence, machine learning, and data analysis. It provides a meeting place for the business, technology, scientific, and administrative communities—a space where implementation practice meets regulatory and strategic reflection.</p>



<p>Link to the event: <a href="https://ml.dssconf.pl/#agenda">https://ml.dssconf.pl/#agenda</a></p>



<p>This year&#8217;s edition focuses on the most important directions of development of modern artificial intelligence, including, among others, generative AI ( Generative AI), large language models (LLM), GPT systems, AI agents, Agent-to-Agent (A2A) architectures, Context Model Protocol (MCP), reinforcement learning, computer vision, predictive analytics, MLOps, LLMOps, AI governance and broadly understood data-driven business transformation.</p>



<p>The conference is aimed at data scientists, AI experts, data engineers, IT system architects, programmers, cybersecurity specialists, digital transformation leaders, product development managers, public administration representatives, and executives of enterprises implementing AI-based solutions. Speakers will include representatives of global technology companies, international corporations, financial institutions, telecommunications operators, energy companies, research and development organizations, academia, and technology startups &#8211; including AI directors, chief system architects, digital transformation leaders, scientists, AI engineers, MLOps experts, cybersecurity specialists, and managers responsible for implementing technological innovations.</p>



<p>The event is distinguished by its practical nature. The program focuses not only on presenting technological innovations, but primarily on showcasing real-world implementations already in place in businesses, public administration, the financial and energy sectors, e-commerce, telecommunications, healthcare, and industry.</p>



<span id="more-8801"></span>



<p><strong><u>Enterprise AI &#8211; From Experiment to Infrastructure</u></strong></p>



<p>One of the most important themes of the conference is the practical use of artificial intelligence in production environments. It is increasingly clear that AI has ceased to be an experimental technology and has become a component of real-world business infrastructure. In this context, we are analyzing ways to counteract the phenomenon of so-called information bubbles and build more sustainable recommendation systems used by the largest media platforms. Methods are emerging to increase the diversity of presented content, reduce algorithmic bias, and design systems that responsibly influence user behavior.</p>



<p>A key issue is the collaboration between classic machine learning and generative AI. Combining both approaches allows for the development of scalable, cost-effective solutions, ready for use by large organizations. A significant portion of the discussion also focuses on countering financial fraud &#8211; methods for detecting fraud and building competitive advantage through structured AI system development processes. Developer experience and modern work environments for AI teams are also gaining importance, including ways to accelerate the creation and maintenance of AI-based applications.</p>



<p>The technological landscape is strongly influenced by the prototyping of AI agents using modern programming environments and platforms supporting the creation of autonomous systems. Simultaneously, there are emerging themes regarding the use of AI in the legal sector &#8211; methods for assessing the reasoning ability of language models, methods for tracing legal sources, and techniques for increasing the reliability of AI-generated responses. From a security perspective, mechanisms for securing autonomous systems against attacks, unauthorized access, and attempts to manipulate their behavior are particularly important.</p>



<p>Equally important is the optimization of language models &#8211; techniques for quantization, distillation, and model size reduction while maintaining high efficiency. In the financial sector, solutions are emerging that include automated document processing, data extraction, and the development of intelligent analytical platforms. As an illustration of the creative potential of AI, the mechanisms behind music generation by artificial intelligence and the application of deep learning in creative processes are also discussed.</p>



<p><strong><u>Generative AI – Multimodality, Agents, and Public Administration</u></strong></p>



<p>Generative AI is one of the fastest-growing areas of contemporary technology. In production practice, it is used to automatically describe works of art, create alternative descriptions that increase the accessibility of digital documents for people with disabilities, and develop strategies for replacing very large and expensive language models with smaller, specialized solutions that can be effectively used in enterprises. The evolution of architectures leads from simple prompts, through RAG mechanisms, to multi-stage pipelines integrating multiple data sources and advanced LLM architectures.</p>



<p>Multimodality plays a significant role &#8211; solutions that can simultaneously analyze text, images, sound, and spatial information &#8211; opening the door to building more versatile AI systems. In enterprise environments where standard communication protocols aren&#8217;t feasible, building agents that exclusively utilize approved APIs, internal tools, and development platforms becomes crucial, while adhering to security and governance principles.</p>



<p>A crucial direction is the use of artificial intelligence in public administration, including the process of transforming an AI project into a product accessible to millions of citizens. Solutions that generate sound, speech, and music using modern diffusion models and transformers are also gaining importance, as are automatic analysis of PDF documents and the extraction of structured data from multi-page administrative materials. Hybrid pipelines combining generative AI, signal processing, and embedded systems for use in resource-constrained devices are also emerging. A separate, increasingly important issue is assessing the quality of RAG chatbots, testing them before deployment, and building reliable conversational systems.</p>



<p><strong><u>Machine learning in practice &#8211; recommendations, energy, finance</u></strong></p>



<p>Classic machine learning remains relevant &#8211; on the contrary, it&#8217;s finding applications in major industrial and financial implementations. Modern recommendation systems are emerging, based on data representation vectors and embedding architectures, where balancing recommendation effectiveness with the ability for users to discover new content is paramount. Digital twins are being used to optimize energy assets and manage industrial infrastructure. In the financial sector, teams of collaborative models are emerging to support decision-making processes.</p>



<p>The challenges associated with AI agents operating in social media are increasingly being discussed &#8211; issues such as user privacy, data security, and customer interaction design. In the banking sector, there&#8217;s a clear trend toward building millions of personalized models operating in parallel, which requires advanced training optimization, system scaling, and efficient processing of massive data sets.</p>



<p><strong><u>Deployments, MLOps, and Security &#8211; The AI Systems Lifecycle</u></strong></p>



<p>One of the most practical areas of the event is implementing, maintaining, and scaling AI systems in production environments. Simply developing a model is no longer the biggest challenge; ensuring its stable, secure, and effective operation in real-world business environments is crucial.</p>



<p>The security of generative AI is becoming one of the most pressing issues. Practical methods are emerging to protect models from prompts, injection, jailbreaking, and attempts to bypass control mechanisms. Referring to OWASP guidelines and modern solutions enabling the implementation of AI systems in accordance with the security- by-design principle is becoming standard.</p>



<p>From a legal perspective, issues related to designing global data platforms operating simultaneously in multiple jurisdictions are particularly important. These challenges include data sovereignty, local regulations, and the need to reconcile legal requirements across different jurisdictions.</p>



<p>A key theme is the full lifecycle of machine learning models &#8211; the processes of building, deploying, monitoring, updating, and retiring AI models, as well as how to manage their performance at scale. System performance optimization plays a significant role &#8211; techniques for reducing latency, shortening inference times, and adapting models to various hardware environments. Case studies from the pharmaceutical sector also appear, demonstrating how to manage chatbots&#8217; deviance from their original purpose and how to minimize the risk of generating undesirable responses. Simultaneously, computer model optimization techniques are being developed, allowing to increase their efficiency many times while maintaining high quality of prediction.</p>



<p>Monitoring LLM systems and AI agents before end-user errors occur is becoming particularly important. Systems for model tracking, automated evaluation, anomaly detection, cost management, and continuous response quality improvement are emerging. Solutions are emerging that enable the management of thousands of AI agents and their evaluation at scale. This is complemented by approaches based on GitMLOps, DevSecOps, and modern observability solutions for systems based on large language models.</p>



<p><strong><u>AI Agents &#8211; Autonomous Decision-Making Systems</u></strong></p>



<p>One of the most important areas of the conference is AI agents. Modern artificial intelligence is increasingly moving beyond the role of a mere tool for human support and instead becoming an autonomous system capable of executing complex business processes. Methods are emerging for assessing the effectiveness of large-scale multi-agent systems &#8211; methods for automated testing, reliability testing, tracing error sources, and building systems that guarantee repeatable results. Significant attention is being paid to monitoring agents in real time, identifying errors, measuring response quality, and continuously improving decision-making processes.</p>



<p>Issues related to the security of AI agents are becoming increasingly important, including attack scenarios that confuse autonomous systems and methods for securing them against manipulation. Practical applications of agents utilizing financial, registry, and business data are emerging, supporting analytical, scoring, and decision-making processes. AI agents are also finding applications in telecommunications and in the construction of systems that independently conduct research and analysis.</p>



<p>Agents&#8217; long-term memory plays a significant role &#8211; solutions utilizing knowledge graphs and mechanisms that enable agents to independently organize and expand their accumulated knowledge. Real-time voice agents are highly practical &#8211; systems capable of conducting telephone conversations with users, analyzing speech, and generating responses that approximate natural communication. Solutions are also emerging that enable automatic detection of problems arising during the operation of production agents and the generation of evaluation processes without human intervention. Applications also include systems supporting energy management, intelligent buildings, and Internet of Things devices. A separate, important area is the evaluation of Text -to-SQL systems, which enable the automatic conversion of natural language into database queries.</p>



<p><strong><u>Development and tuning of large language models</u></strong></p>



<p>A significant portion of the conference was devoted to the creation, training, and refinement of large-scale language models. The most common errors made when building AI models are increasingly understood, as is the significant impact that the proper selection of training data has on their quality. Specialized models for the banking sector are being developed, along with methods for adapting them to specific business applications.</p>



<p>A significant area of research is Polish multimodal models capable of simultaneously understanding text and images, including methods for building them with limited data resources. Techniques for simplifying official and administrative language using language models are also emerging, with a particular emphasis on increasing the accessibility of public transportation. Mechanisms for building trust in artificial intelligence by providing users with justifications for generated responses are gaining increasing importance. Embedding models, used to identify duplicate data, ambiguous names, and unstructured addresses, are becoming increasingly important in everyday business practice.</p>



<p><strong><u>Business Transformation &#8211; Strategy, Data, and Organization</u></strong></p>



<p>From a strategic perspective, artificial intelligence is becoming one of the most important elements in building a competitive advantage for enterprises. Practical experience is emerging with implementing generative AI in international organizations and managing technological transformation processes. Methods for identifying the most promising AI initiatives from among hundreds of potential projects are becoming increasingly important.</p>



<p>Data quality plays a significant role &#8211; proper data preparation is now a prerequisite for the effective implementation of artificial intelligence. Critical analysis of technological trends is also emerging, allowing us to separate the true capabilities of AI from marketing hype. The importance of data architecture and IT systems for the success of transformation projects is becoming increasingly clear. The debate on the future of management in the era of agent-based AI and the changes AI will bring to corporate organizational structures is particularly prominent. Examples of building scalable customer service agents operating simultaneously in multiple countries are also emerging, as are the experiences of large organizations implementing AI, developing data products, supporting business expansion, and transforming the banking sector.</p>



<p><strong><u>AI in Software Development &#8211; Regulation, Security, and Intellectual Property</u></strong></p>



<p>Artificial intelligence is fundamentally changing the way technology teams work. Building local systems to support programming in compliance with European regulations, including the AI Act and NIS2, is becoming increasingly important. Both the potential and limitations of modern programming assistants are emerging, including the reasons for the failure of AI agents working with enterprise data and ways to build more predictable systems.</p>



<p>Cybersecurity, threat modeling, and vulnerability management in AI-based systems are all important topics, as are the practical aspects of building agent platforms capable of operating in production environments. From a legal perspective, issues related to intellectual property protection, commercialization of AI-based solutions, copyright management, and building secure technological product development processes are particularly important.</p>



<p><strong><u>Computer Vision &#8211; intelligent image analysis</u></strong></p>



<p>Modern image analysis goes far beyond classical object recognition. New approaches are emerging to using visual models in unusual applications, including Visual RAG systems that enable automated processing of data contained in spreadsheets and corporate documents. The technological trade-offs involved in designing high-performance pipelines are increasingly understood. computer vision. Computer vision is also used in climate forecasting and analysis of environmental phenomena, as well as in automatic data extraction from Polish administrative and business documents.</p>



<p><strong><u>Debates about the future of artificial intelligence</u></strong></p>



<p>An integral part of the event are expert roundtable discussions. The role of software agents is discussed &#8211; whether they will become merely a tool to support specialists or will they take over some of their responsibilities. The use of AI agents as digital equivalents of junior engineers supporting data science teams is also discussed. Experts engage in debates on the labeling of AI-generated content and the transparency of AI systems.</p>



<p>A separate discussion is devoted to Europe&#8217;s technological sovereignty and the possibility of building an independent artificial intelligence ecosystem. The discussion concludes with a discussion on the competencies of the future and the skills that will become crucial for organizations to function in an AI-based economy.</p>



<p>The Data Science Summit AI Edition 2026 demonstrates that artificial intelligence is no longer just a technology of the future. It has become one of the most important tools shaping modern businesses, public administration, and the financial, energy, industrial, and technology sectors. The scale and scope of the topics covered confirm that AI development today requires not only advanced technological competencies but also appropriate risk management, security, regulatory compliance, and a responsible approach to implementing new technologies &#8211; making law firms&#8217; participation in such events a natural part of tracking the directions in which new technologies law is heading.</p>



<p>#DataScienceSummit #AIEdition2026 #ArtificialIntelligence #AI #MachineLearning #GenerativeAI #LLM #GPT #AIAgents #AgenticAI #AgentToAgent #ModelContextProtocol #MCP #DeepLearning #ReinforcementLearning #ComputerVision #PredictiveAnalytics #MLOps #LLMOps #AIGovernance #ResponsibleAI #AIEthics #AISecurity #PromptInjection #Jailbreaking #SecurityByDesign #OWASP #DevSecOps #GitMLOps #CyberSecurity #DataSovereignty #AIAct #NIS2 #EURegulations #TechSovereignty #DigitalTransformation #BusinessTransformation #DataDriven #DataQuality #DataEngineering #DataScience #CloudComputing #RAG #VisualRAG #Multimodal #Multimodality #Embeddings #VectorSearch #Quantization #ModelDistillation #FineTuning #TextToSQL #KnowledgeGraphs #VoiceAgents #ConversationalAI #Chatbots #DigitalTwins #IoT #SmartBuildings #EnergyManagement #FinTech #BankingAI #LegalTech #LawFirm #IntellectualProperty #Copyright #PublicAdministration #GovTech #HealthcareAI #PharmaAI #Telecommunications #SoftwareDevelopment #AIAssistants #CodingAgents #Innovation #TechConference #Warsaw #CEE #KGLegal #KieltykaGladkowski</p>


<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/representatives-of-our-law-firm-kg-legal-kieltyka-gladkowski-will-take-part-in-the-data-science-summit-ai-edition-2026-one-of-the-largest-events-dedicated-to-artificial-intelligence-in-centr/">Representatives of our law firm KG LEGAL KIEŁTYKA GŁADKOWSKI will take part in the Data Science Summit AI Edition 2026 – one of the largest events dedicated to artificial intelligence in Central and Eastern Europe</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/kg-legal-news/representatives-of-our-law-firm-kg-legal-kieltyka-gladkowski-will-take-part-in-the-data-science-summit-ai-edition-2026-one-of-the-largest-events-dedicated-to-artificial-intelligence-in-centr/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Current status of pharmacovigilance in Poland under Polish and EU provisions</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/current-status-of-pharmacovigilance-in-poland-under-polish-and-eu-provisions/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/current-status-of-pharmacovigilance-in-poland-under-polish-and-eu-provisions/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Oct 2025 17:58:13 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[marketing authorization holder (MAH)]]></category>
		<category><![CDATA[pharmacovigilance in Poland]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8348</guid>

					<description><![CDATA[<p>Publication date: October 07, 2025 Pharmacovigilance under Polish law The purpose of an inspection of the pharmacovigilance system for medicinal products intended for human use (pharmacovigilance inspection) is to verify how the marketing authorization holder for medicinal products is fulfilling its obligations regarding the pharmacovigilance system imposed by Polish and European Union law. Inspection Basis [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/current-status-of-pharmacovigilance-in-poland-under-polish-and-eu-provisions/">Current status of pharmacovigilance in Poland under Polish and EU provisions</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: October 07, 2025</mark></strong><br><br><strong>Pharmacovigilance under Polish law</strong></p>



<p>The purpose of an inspection of the pharmacovigilance system for medicinal products intended for human use (pharmacovigilance inspection) is to verify how the marketing authorization holder for medicinal products is fulfilling its obligations regarding the pharmacovigilance system imposed by Polish and European Union law.</p>



<span id="more-8348"></span>



<p><strong>Inspection Basis</strong></p>



<p>Inspections of the pharmacovigilance system are conducted by inspectors from the Department of the Inspection of Medicinal Products and Medical Devices, authorized by the President of the Office. Inspectors are authorized to:</p>



<p>&#8211; inspect the marketing authorization holder (MAH) regarding the pharmacovigilance system</p>



<p>&#8211; request documentation related to ensuring the functioning of the pharmacovigilance system</p>



<p>&#8211; request clarification regarding ensuring the functioning of the pharmacovigilance system</p>



<p><strong>Inspection Process</strong></p>



<p>The inspection of the pharmacovigilance system consists of, among other things:</p>



<p>&#8211; verification of the pharmacovigilance system documentation</p>



<p>&#8211; interviews with responsible employees, including the QPPV</p>



<p>&#8211; checking databases</p>



<p>&#8211; insight into the organizational procedures</p>



<p><strong>Inspection</strong></p>



<p>The inspection begins with an opening meeting, which serves to introduce the inspection team and define the purpose and scope of the inspection.</p>



<p>The team will need a room/office where they can interview relevant employees and review documentation.</p>



<p>On the last day of the inspection, during a closing meeting, the inspection team presents their observations and describes any discrepancies in the functioning of the pharmacovigilance system.</p>



<p><strong>What information do inspectors expect from the entity subject to inspection?</strong></p>



<p>Before commencing the inspection, the marketing authorization holder (MAH) is requested to submit a copy of the full description of the Pharmacovigilance Management System (PSMF).</p>



<p>In addition, the MAH should provide inspectors with access to documentation regarding, among other things:</p>



<p>&#8211; standard operating procedures, work instructions,</p>



<p>&#8211; source documentation for individual case reports (ICSRs),</p>



<p>&#8211; periodic safety update reports (PSURs),</p>



<p>&#8211; risk management plans for the use of the medicinal product,</p>



<p><strong>Inspection Report</strong></p>



<p>The results of the inspection are presented in an inspection report, which is prepared within 30 days of the inspection completion date. The report is then submitted to the President of the Office for approval. The approved report is forwarded to the MAH.</p>



<p><strong>Types of Inspections:</strong></p>



<p>Routine inspection &#8211; conducted after prior notification to the MAH, sent no later than 30 days before the planned inspection.</p>



<p>Targeted inspections are conducted after prior notification to the responsible entity, sent no later than 14 days prior to the planned inspection.</p>



<p>Unannounced inspections are conducted when there is a suspicion that a system malfunction poses a threat to patient life.</p>



<p>It is worth pointing out that apart from Article 24a of Pharmaceutical Law, Chapter 2 of the Act also applies (Article 36b-36z). The Pharmaceutical Law Act regulates pharmacovigilance, in a scope much broader than the inspection itself. The said chapter defines the tasks of the President of Office for the Registration of Medicinal Products, situations in which the Act imposes the obligation to report adverse reactions to the President of the Office, the patient&#8217;s right to report adverse reactions, and, among others, the obligations of the marketing authorization holder (MAH) who has obtained a marketing authorization (MAH &#8211; Marketing Authorization Holder), which include, for example, maintaining a pharmacovigilance system, appointing a person responsible for safety surveillance and reporting his/her data to the President of the Office, collecting, registering and reporting adverse reactions to medicinal products, presenting, at each request of the President of the Office, within 7 days, a copy of the full description of the safety surveillance system for medicinal products, conducting regular audits, and cooperating with the EMA.</p>



<p><strong>Control under European law:</strong></p>



<p>Significant changes have occurred with the publication of Commission Implementing Regulation (EU) 2025/1466 of 22 July 2025, amending Implementing Regulation (EU) No 520/2012 on activities related to pharmacovigilance. The changes are of various nature, including, among others, reducing the administrative obligations regarding the pharmacovigilance system master file. Implementing Regulation (EU) No 520/2012 specifies, among other things, the content of the pharmacovigilance system master file. To avoid unnecessary administrative burden for applicants and competent authorities, only significant deviations from pharmacovigilance procedures, their impact and their management until the issue is resolved should be documented in the pharmacovigilance system master file, which in particular implies an amendment to Article 4(3).</p>



<p>The same Implementing Regulation introduced new requirements for subcontracting arrangements (added Article 6(3) and (4) and Article 13(1a) of Regulation 520/2012). The marketing authorisation holder may subcontract certain pharmacovigilance system tasks to third parties. However, the main MAH retains full responsibility for the completeness and accuracy of the pharmacovigilance system master file and that the marketing authorisation holder shall draw up a list of existing subcontracting arrangements between himself and third parties. The marketing authorisation holder shall include the following elements in subcontracting agreements: (a) a clear description of the roles and responsibilities of third parties to whom pharmacovigilance activities are subcontracted; (b) a provision obliging third parties to exchange safety data with the marketing authorisation holder and, where appropriate, the method for exchanging safety data; (c) arrangements for the third-party inspection and audit process; (d) a provision obliging third parties to agree to be audited by or on behalf of the marketing authorisation holder and to be inspected by the competent authorities.</p>



<p>Article 13 of the Regulation addresses the auditing requirements imposed by the European legislator on marketing authorization holders. The new wording states in paragraph 1 that: Marketing authorization holders shall conduct risk-based audits of the quality system at regular intervals to ensure its compliance with the requirements set out in Articles 8, 10, 11, and 12 and to determine its effectiveness. Audits, taken individually or in combination, shall cover all pharmacovigilance activities during a designated period and shall verify their compliance with the policies, processes, and procedures defined within the quality system. Audits shall be carried out by persons who are not directly involved in, or responsible for, the matters or procedures being audited. The added paragraph 1a provides that any third party subcontracted to perform all or part of the pharmacovigilance tasks on behalf of marketing authorisation holders or in collaboration with them shall be subject to an audit by or on behalf of the marketing authorisation holders, taking into account the risks associated with subcontracting, and may be subject to an inspection by the competent authorities, even if the subcontracting agreement does not yet include the obligation under Article 6(3).</p>



<p>In addition to audits at regular intervals, audits must be carried out when necessary, including corrective actions and a follow-up audit for non-compliance (Article 13(2)).</p>



<p>The periodic safety update report, in accordance with Article 34 of Commission Implementing Regulation No. 520/2012, contains the results of assessments of the effectiveness of risk minimization activities relevant to the risk-benefit assessment, and from February 2026, will also include information on the implementation of risk minimization measures and the results of the assessment of the effectiveness of the actions taken (Article 34, paragraph 3, new wording).</p>



<p>Another new obligation on the part of MAHs (marketing authorization holders) is to post information on post-authorization safety studies in the EMA electronic register (Article 36, paragraph 5, new wording).</p>



<p>All the changes mentioned above come into force on February 12, 2026; however, the obligation to actively use the EudraVigilance database is different. The amended Article 18, paragraphs 2 and 3 of Regulation 520/2012 obliges MAHs to monitor, but also to use data from the EudraVigiliance database in combination with data from other sources. This obligation has already entered into force, on 12 August 2025, unlike other amendments.</p>



<p>Recital 5 of Commission Implementing Regulation (EU) 2025/1466 explains: &#8220;The Eudravigilance database is a system for managing and analysing information on adverse reactions to medicines authorised or undergoing clinical trials. The European Medicines Agency (&#8220;the Agency&#8221;) and national competent authorities continuously monitor the data in the Eudravigilance database. Marketing authorisation holders also have access to the database to the extent necessary to fulfil their pharmacovigilance obligations. Based on the experience of marketing authorization holders in monitoring data in the Eudravigilance system, the requirements for marketing authorization holders should be clarified, including requirements for approving signals and notifying them to the Agency and national competent authorities. Recital 7 states: &#8220;Individual cases of suspected adverse reactions to a medicinal product shall be reported to the Eudravigilance database. Such reports should contain as much information as possible, and to partially standardize them, minimum reporting requirements should be applied to all cases.&#8221;</p>



<p>Additionally, Regulation 520/2012 also regulates other issues. Chapter I specifies the pharmacovigilance system master file in terms of structure, content of the system master file and the content of the annex to the system master file. It also introduces rules for system maintenance and specifies the format of documents included in the pharmacovigilance system master file. Chapter II, in turn, specifies the minimum requirements for quality systems for pharmacovigilance activities conducted by marketing authorization holders (the regulations specify the activities covered by the quality system, the requirements that marketing authorization holders must meet in terms of human resources management, e.g., appropriately qualified staff, and the obligation to implement quality procedures and processes to ensure data monitoring, risk minimization, and prevention.</p>



<p>The regulations also specify how data should be recorded and stored, as well as the principles and obligation to conduct audits). The following chapters cover: minimum requirements for data monitoring in the Eudravigilance database, terminology (according to recital 12, the use of terminology, formats, and standards at international level should facilitate the interoperability of systems used for pharmacovigilance activities and avoid duplication of coding of activities concerning the same information. It should also enable easier exchange of information between regulatory authorities at international level), the submission of reports on suspected adverse drug reactions, risk management plans, and periodic safety update reports.</p>



<p>The marketing authorisation holder shall submit the study protocol, the abstract of the final study report and the final study report submitted in accordance with Articles 107n and 107p of Directive 2001/83/EC in English, except for studies conducted in only one Member State and required pursuant to Article 22a of Directive 2001/83/EC. For such studies, the marketing authorisation holder shall submit an English translation of the title and abstract of the study protocol and an English translation of the summary of the final study report.</p>



<p>The marketing authorisation holder shall ensure that all information relating to the trial is recorded and stored in a manner that allows for accurate reporting, assessment and verification of information, and ensures the confidentiality of data relating to trial participants. The marketing authorisation holder shall ensure that the analytical dataset and statistical programmes used to generate the data included in the final trial report are stored electronically and made available for audit and inspection purposes.</p>



<p>When analysing the pharmacovigilance control system, one cannot ignore the so-called soft law, of which the EMA guidelines stand out in particular, such as the Guidelines on Good Pharmacovigilance Practices (GVP) – Module VIII: Post- authorisation safety studies. At this point, the current, applicable version of the GVP Module VIII rev. 3 guidelines has been in force since 2017. The purpose of this document is to ensure a uniform approach in the EU to the design and supervision of PASS (Post- authorization Safety Studies) and to support the relevant authorities (in Poland, this is the President of the office, mentioned earlier) and marketing authorization holders (MAHs). Due to the recent adoption of Implementing Regulation 2025/1466, the adoption of new guidelines, the so-called GVP Module VIII rev. 4, is expected in the near future.</p>



<p>Due to the importance of both Polish and European regulations, and due to the high importance of the guidelines published by the EMA, on May 29, 2025, the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products issued information on studies on the safety and efficacy of the use of a medicinal product conducted after the issuance of authorization – PASS and PAES. It includes, among other things, that: A study on the safety of the use of a medicinal product conducted after the issuance of authorization (Post- authorization safety study (PASS) may be undertaken by the marketing authorisation holder voluntarily or as a result of an obligation imposed by the President of the Office, if there are concerns about the risk associated with the use of a medicinal product or if it is necessary to assess the effectiveness of the measures taken to reduce this risk. If the study will be conducted exclusively in the territory of the Republic of Poland, the marketing authorisation holder shall submit the study protocol to the President of the Office, who shall assess it. Protocols of studies to be conducted in more than one EU Member State should be submitted to the Pharmacovigilance Risk Assessment Committee, which assesses the appropriateness of the proposed protocol. The principles for preparing study protocols and their conduct are included in Commission Implementing Regulation (EU) No 520/2012, Guideline on good pharmacovigilance practices (GVP), Module VIII – Post- authorisation safety studies. It was also indicated that the marketing authorisation holder should register the conducted study in the electronic register maintained by the European Medicines Agency (EMA).</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/current-status-of-pharmacovigilance-in-poland-under-polish-and-eu-provisions/">Current status of pharmacovigilance in Poland under Polish and EU provisions</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/current-status-of-pharmacovigilance-in-poland-under-polish-and-eu-provisions/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Alternative Investment Companies – practical comments</title>
		<link>https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/alternative-investment-companies-practical-comments/</link>
					<comments>https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/alternative-investment-companies-practical-comments/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Mon, 02 Dec 2024 17:45:09 +0000</pubDate>
				<category><![CDATA[INVESTMENT LAW AND PROCESSES IN POLAND]]></category>
		<category><![CDATA[Alternative Investment Companies]]></category>
		<category><![CDATA[cross border cases]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[Poland]]></category>
		<category><![CDATA[Polish law]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=7588</guid>

					<description><![CDATA[<p>Alternative Investment Companies – practical comments</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/alternative-investment-companies-practical-comments/">Alternative Investment Companies – practical comments</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: December 02, 2024</mark></strong></p>



<p>Alternative investment companies are a specific form of investment activity introduced into the Polish legal system within the framework of the provisions on investment funds, and specifically in the context of managing alternative investment funds. These regulations are contained in the Act of 27 May 2004 on investment funds and the Act of 22 July 2005 on the management of alternative investment funds<em>, Journal of Laws 2024.1034</em>. AIICs are therefore a specific form of asset management that creates the possibility of investing in alternative assets, such as real estate, private equity, raw materials or debt, while maintaining high flexibility in terms of investment strategies.</p>



<p><strong>Legal Basis for Alternative Investment Companies</strong></p>



<span id="more-7588"></span>



<p>Alternative investment companies are regulated in the Polish legal system by the aforementioned acts on investment funds and on the management of alternative investment funds. In particular, their functioning is associated with the appropriate transformation of the legal form of investment funds, which can operate as capital companies. This means that Alternative Investment Companies are joint-stock companies or limited liability companies that can invest in a wide range of alternative assets.</p>



<p>Pursuant to Article 8a of the Act, alternative investment companies may conduct business in two forms, namely as:</p>



<p>&#8211; limited liability companies, joint-stock companies or European companies;</p>



<p>&#8211; limited partnerships or limited joint-stock partnerships in which the sole general partner is a limited liability company, joint-stock company or European company.</p>



<h2 class="wp-block-heading"><strong>Key Features of Alternative Investment Companies</strong></h2>



<p>Legal form: According to the Investment Funds Act, alternative investment companies may take the form of a joint-stock company or a limited liability company. This means that investors acquire shares or stocks in such companies, which then invest these funds in accordance with a specific investment strategy.</p>



<p>Investment scope: Alternative investment companies, in accordance with the Act on the Management of Alternative Investment Funds, have the ability to invest in a wide range of assets, including:</p>



<p>&#8211; Real estate,</p>



<p>&#8211; Unlisted companies (private equity),</p>



<p>&#8211; Raw materials (e.g. gold, oil),</p>



<p>&#8211; Debt instruments (e.g. investments in corporate debt),</p>



<p>&#8211; Derivatives and other non-standard assets.</p>



<p>The Investment Funds Act provides great flexibility in the selection of investment instruments, which allows for the implementation of more complex investment strategies.</p>



<p>In accordance with Article 8b of the Act of 27 May 2004 on Investment Funds and the Act of 22 July 2005 on the Management of Alternative Investment Funds (AIF)<em>, Journal of Laws 2024, item 1034</em>,</p>



<p>Alternative investment companies are managed by a so-called investment fund manager, which in the case of alternative investment company plays a role equivalent to the management board of an investment fund. In managing this fund, it is important that the people responsible for investment decisions have the appropriate qualifications and experience, and also comply with the requirements related to capital market regulations. Fund managers have an obligation of transparency, responsibility and compliance with legal regulations.</p>



<p><strong><u>Participant Restrictions: In the case of alternative investment companies, as in other investment funds, there are specific regulations regarding the group of investors.</u></strong> According to the Act on the Management of Alternative Investment Funds, alternative investment companies are intended mainly for professional investors who meet certain criteria, such as the minimum investment value or the status of a professional investor (e.g. financial institutions, wealthy individual investors). Such funds are not aimed at the general public.</p>



<p>According to art. 8c of the Act, an investor in an alternative investment company is an entity that holds participation rights in an alternative investment company and meets the criteria of a professional client. The criteria of a professional client shall not apply if the alternative investment company has obtained the authorization referred to <em>in art. 5 sec. 1 of the Regulation 2015/760 on European long-term investment funds, OJ EU.L.2015.123.98 of 2015.05.19.</em></p>



<p>The participation rights of an alternative investment company are, respectively, a share in the company and a stock.</p>



<p>In the case of a limited partnership and a limited joint-stock partnership, participation in a company is understood as all the rights and obligations of a partner in the company.</p>



<p>An entity meeting the criteria of a professional client may make a contribution to an alternative investment company in exchange for participation rights in that company.</p>



<p>The subject of a contribution to an alternative investment company operating in the form of a limited partnership may not be an inalienable right or the provision of work or services.</p>



<p>The alternative investment company manager who manages an alternative investment company investing assets in shares of companies admitted to trading on a regulated market shall prepare and publish an engagement policy that describes how the engagement of shareholders of such companies is taken into account by the alternative investment company in its investment strategy. The manager of an alternative investment company shall prepare and publish an annual report on the implementation of the policy. The report shall include in particular:</p>



<p>&#8211; general description of voting procedure;</p>



<p>&#8211; description of the most important votes;</p>



<p>&#8211; description of the method of using the services of a shareholder voting advisor, referred to in <em>Article 4 § 1 item 16 of the Commercial Companies Code, Journal of Laws 2000 No. 94 item 1037.</em></p>



<p>An alternative investment company may be marketed among:</p>



<p>&#8211; professional clients;</p>



<p>&#8211; retail clients &#8211; in the event that it has obtained the authorisation referred to in Article 5 paragraph 1 of Regulation 2015/760.</p>



<p>The manager of an alternative investment company is obliged to notify the Commission in writing of the intention to introduce an alternative investment company to trading in the territory of the Republic of Poland.</p>



<h2 class="wp-block-heading"><strong>Capital</strong></h2>



<p>Initial capital for conducting business activity:</p>



<p>&#8211; in respect to externally managed alternative investment company &#8211; amounts to at least the equivalent of EUR 125,000 expressed in PLN,</p>



<p>&#8211; in respect to internally managed alternative investment company &#8211; amounts to at least the equivalent of EUR 300,000 expressed in PLN;</p>



<p>&#8211; using the average exchange rate announced by the National Bank of Poland on the last business day preceding the date of submission of the application for a permit to perform business activity by the manager of the alternative investment company.</p>



<p>Initial capital shall be understood as the sum of the share capital in the amount in which it was paid up together with the issue premium, undistributed profits from previous years, as well as the net profit in the process of approval, provided that this profit results from the financial statements audited by a statutory auditor, and the reserve capital, reduced by the uncovered loss from previous years.</p>



<p><strong>Benefits and Challenges of Alternative Investment Companies</strong></p>



<p><strong>Benefits</strong></p>



<p>Flexibility in asset selection – Alternative investment companies have the ability to invest in a wider range of assets than traditional investment funds. This includes the ability to invest in real estate, private equity, venture capital or commodities, which allows for greater diversification of the investment portfolio.</p>



<p><strong>Tax benefits – the Investment Funds Act provides tax preferences for alternative investment companies, which means that profits earned by these companies may be exempt from income tax, provided that the company meets certain conditions regarding the investment structure and activities.</strong></p>



<p>Access to Niche Markets – Alternative investment companies can invest in assets that are hard to access or non-traditional in traditional markets, giving investors the opportunity to participate in profitable but riskier markets.</p>



<p><strong>Challenges</strong></p>



<p>Higher risk – Due to their flexibility in asset selection, alternative investment companies often invest in riskier assets, which is associated with a higher potential return, but also with greater risk. Risk can also result from the illiquidity of some of the assets in which these companies invest.</p>



<p>Lack of liquidity – Many of the investments of alternative investment companies (e.g. real estate and private equity) are illiquid. This means that investors may have difficulty selling their holdings in the short term, which may limit their ability to exit their investment if necessary.</p>



<p>Regulatory Complexity – Managing alternative investment funds involves meeting specific regulatory requirements, both domestic and EU.</p>



<p><strong>Summary</strong></p>



<p>Alternative investment companies are an attractive form of investment that offers great flexibility in terms of asset selection and investment strategies. Based on the provisions of the Act on Investment Funds and on the Management of Alternative Investment Funds, alternative investment companies can invest in a wide range of alternative assets, which allows for the implementation of complex investment strategies, but at the same time involves higher risk. For this reason, alternative investment companies are mainly aimed at professional investors and require extensive experience in investing.</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/alternative-investment-companies-practical-comments/">Alternative Investment Companies – practical comments</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/investment-law-and-processes-in-poland/alternative-investment-companies-practical-comments/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>KIELTYKA GLADKOWSKI KG LEGAL TAKES PART IN THE EVENT “KRAKÓW: City – space for business. Synergy for the reconstruction of Ukraine”, January 15, 2024</title>
		<link>https://www.kg-legal.eu/info/kg-legal-news/kieltyka-gladkowski-kg-legal-takes-part-in-the-event-krakow-city-space-for-business-synergy-for-the-reconstruction-of-ukraine-january-15-2024/</link>
					<comments>https://www.kg-legal.eu/info/kg-legal-news/kieltyka-gladkowski-kg-legal-takes-part-in-the-event-krakow-city-space-for-business-synergy-for-the-reconstruction-of-ukraine-january-15-2024/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Mon, 11 Dec 2023 11:56:23 +0000</pubDate>
				<category><![CDATA[KG LEGAL NEWS]]></category>
		<category><![CDATA[cross border cases]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[gładkowski]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[Poland]]></category>
		<category><![CDATA[reconstruction of Ukraine]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=5915</guid>

					<description><![CDATA[<p>Publication date: December 11, 2023 On January 15, 2024, there will be held the event KRAKÓW: City – space for business. Synergy for the reconstruction of Ukraine. The event is organized by the Polis-Ukrainian Chamber of Commerce within the framework of the social campaign &#8220;Partnership and Employment&#8221; and the project &#8220;Work for Reconstruction of Entrepreneurship [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/kieltyka-gladkowski-kg-legal-takes-part-in-the-event-krakow-city-space-for-business-synergy-for-the-reconstruction-of-ukraine-january-15-2024/">&lt;strong&gt;KIELTYKA GLADKOWSKI KG LEGAL TAKES PART IN THE EVENT “KRAKÓW: City – space for business. Synergy for the reconstruction of Ukraine”, January 15, 2024&lt;/strong&gt;</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><kbd><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: December 11, 2023</mark></strong></kbd></p>


<div class="wp-block-image">
<figure class="alignleft size-large is-resized"><img decoding="async" src="https://www.kg-legal.eu/wp-content/uploads/2023/12/2024-01-15-MIASTO-PRZESTRZEN-DLA-BIZNESU-1024x535.png" alt="" class="wp-image-5916" width="432" height="225" srcset="https://www.kg-legal.eu/wp-content/uploads/2023/12/2024-01-15-MIASTO-PRZESTRZEN-DLA-BIZNESU-1024x535.png 1024w, https://www.kg-legal.eu/wp-content/uploads/2023/12/2024-01-15-MIASTO-PRZESTRZEN-DLA-BIZNESU-300x157.png 300w, https://www.kg-legal.eu/wp-content/uploads/2023/12/2024-01-15-MIASTO-PRZESTRZEN-DLA-BIZNESU-768x402.png 768w, https://www.kg-legal.eu/wp-content/uploads/2023/12/2024-01-15-MIASTO-PRZESTRZEN-DLA-BIZNESU.png 1201w" sizes="(max-width: 432px) 100vw, 432px" /></figure></div>


<p>On January 15, 2024, there will be held the event <strong>KRAKÓW: City – space for business. Synergy for the reconstruction of Ukraine</strong>. The event is organized by the Polis-Ukrainian Chamber of Commerce within the framework of the social campaign &#8220;Partnership and Employment&#8221; and the project &#8220;Work for Reconstruction of Entrepreneurship in Ukraine.” The event will provide a unique platform for diverse professionals, thought leaders, and stakeholders to come together and discuss critical issues surrounding urban development, business opportunities, and collaborative efforts for the reconstruction of Ukraine. The conference will cover a wide range of topics such as urban planning, sustainable development, and the role of businesses in contributing to the reconstruction efforts in Ukraine. Renowned experts and speakers will share valuable insights, best practices, and innovative ideas, fostering a rich exchange of knowledge and experience. Participation in the Conference will be an enriching experience. The insights we will gain and connections made will undoubtedly contribute to our professional growth. The event will be participated by Weronika Mazurek on behalf of KIELTYKA GLADKOWSKI KG LEGAL.</p>



<span id="more-5915"></span>


<div class="components-placeholder"><div class="notice notice-error"><strong>RSS Error:</strong> WP HTTP Error: cURL error 60: SSL certificate OpenSSL verify result: self signed certificate in certificate chain (19)</div></div>


<p></p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/kieltyka-gladkowski-kg-legal-takes-part-in-the-event-krakow-city-space-for-business-synergy-for-the-reconstruction-of-ukraine-january-15-2024/">&lt;strong&gt;KIELTYKA GLADKOWSKI KG LEGAL TAKES PART IN THE EVENT “KRAKÓW: City – space for business. Synergy for the reconstruction of Ukraine”, January 15, 2024&lt;/strong&gt;</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/kg-legal-news/kieltyka-gladkowski-kg-legal-takes-part-in-the-event-krakow-city-space-for-business-synergy-for-the-reconstruction-of-ukraine-january-15-2024/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
